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Flavin-containing monooxygenases (FMOs) are a family of membrane-bound 
xenobiotic metabolizing enzymes, found in the tissues of most mammals, including 
humans. Five distinct FMO enzymes are known, each encoded by a single gene. 
FMOs catalyze the oxidation of a variety of soft nucleophiles, including nitrogen, 
sulfur, and phosphorus-containing compounds. Generally, FMO oxidizes compounds 
to less toxic metabolites, but examples of FMO-mediated metabolic activation of 
chemicals to carcinogens or toxicants is known. Overall, FMOs play a significant role 
in xenobiotic metabolism and determination of chemical toxicity. FMO expression is 
known to be tissue- and species-specific, and modulated by glucocorticoids and sex 
steroids. The objective of this research was to determine the developmental regulation 
of FMOs, since little is known of the ability of the fetus or neonate to metabolize 
xenobiotics. Developmental expression of two major isoforms, FMO1 and FMO2 were 
found to be present at significant levels in the lung and liver of fetal and neonatal rabbit. 
Induced to significant levels by the honnonal milieu of the mother, these isoforms can 
therefore play a significant role in the transformation of xenobiotics through both 
lactational and transplacental exposures. Since many naturally-occurring components 
Redacted for Privacyin the diet have enzyme modulating properties, dietary regulation of FMOs was also 
investigated. Indole-3-carbinol (13C), a chemical present in high levels in cruciferous 
vegetables, which has been shown to exhibit anti-estrogenic activity, and is capable 
of inducing a number of isoforms of cytochromes P450 (CYPs) was chosen for 
experimentation. Addition of I3C to the diets of rats significantly down-regulated 
FMO expression and activity in both a time- and dose-dependent manner, with 
concurrent induction of CYP1A1 . The net result could be a dramatic shift from FMO-
to CYP-dependent monooxygenation for substrates that are metabolized by both 
systems. Dietary 13C supplementation in pregnant rats demonstrated that certain 13C 
derivatives can cross the maternal placenta, resulting in sex-dependent induction of 
CYP1A1 and CYP1B1 in neonatal liver, thereby significantly altering the overall 
xenobiotic-metabolizing profile of the neonate.  Finally, in vitro assays performed 
with purified I3C acid condensation products demonstrated that the HPLC-purified 
oligomers indolo-carbazole (ICZ), diindolylmethane (133') and hydroxymethyl-
diindolylmethane (HI-1M) inhibited FMO1, and to a lesser extent, FMO2. These 
studies indicate that FMO isoforms are regulated both dietarily and developmentally, 
and can play a significant role in in vivo metabolism. °Copyright by Shelley A. Larsen-Su  
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Chapter 1 
INTRODUCTION 
S.A. Larsen-Su and D.E. Williams 
Department of Environmental and Molecular Toxicology  
Oregon State University, Corvallis, OR  2 
THE FMO GENE FAMILY 
The mammalian flavin-containing monooxygenases (FMOs) (EC 1.14.13.8) 
consist of a multigene family of membrane-bound xenobiotic metabolizing enzymes 
that catalyze the NADPH-dependent oxidation of a wide variety of soft nucleophilic 
substrates containing nitrogen, sulfur, phosphorus, boron, iodine and selenium 
heteroatoms (1, 2). FMO oxidation of drugs, pesticides, and other xenobiotics usually 
leads to the excretion of more polar metabolites, and is generally considered a 
detoxification pathway (3-5). However, in a few instances, FMOs metabolize some 
compounds to toxic, or even carcinogenic end-products (6, 7). Expression of at least 
one FMO isoform can be found in every mammalian tissue type (with the exception of 
muscle), yet their endogenous function is still unknown. The ubiquitous nature of FMO 
expression, coupled with their wide substrate specificity, seems to indicate an important 
role for FMO enzymes in determination of xenobiotic toxicity. 
Although FMO was first described by Ziegler in 1971 (8), it was considered to 
be a novel flavin-containing enzyme limited to pig liver tissue only. In 1977 Devereux 
et al. observed differential rates of dimethylaniline N-oxidation in pig liver versus 
rabbit lung preparations exposed to the divalent metals Hg+2 and Mg+2 (9). From 
1982-84 Ohmiya and Mehendale published three papers describing differences in the 
N-oxidation of chlorpromazine, dimethylaniline and imipramine by microsomes 
isolated from rat and rabbit liver (10-12). Finally, Williams et al. (13) and Tynes et al. 
(14) demonstrated conclusively that more than one FMO form existed, by purifying and 
characterizing distinct forms of FMO from porcine liver and rabbit lung. Both FMO 3 
isoforms oxidize their substrates via molecular oxygen, utilizing NADPH and FAD, but 
can easily be identified by their many differences, which include different pH optima, 
sensitivity to non-ionic detergents, unique substrate specificites, and major differences 
in their thermal stability (Table 1.1). In addition, antibodies raised against the rabbit 
pulmonary form fail to recognize the pig liver FMO, and conversely, antibodies raised 
to pig liver FMO do not cross-react with rabbit lung FMO. 
FMO  P450 
Temperature:  labile  stable 
pH optima:  8.4 - 10.5  7.0 - 8.0 
Methimazole:  substrate  inhibitor 
n-octylamine:  activator/substrate  inhibitor 
Carbon monoxide:  no effect  inhibitor 
Cimetidine or SKF 525:  no effect  inhibitor 
Antibody to P450:  no effect  inhibitor 
Antibody to P450 reductase:  no effect  no effect 
Pre-treat w/P450 inducers:  no effect  stimulates 
Treat w/non-ionic detergent:  no effect  inactivates 
Table 1.1 Methods to Distinguish FMO versus P450 Activities. 
The discovery of a second distinct FMO isoform in rabbit lung, demonstrated 
that FMO existed in multiple forms, in multiple species, and in multiple tissue types, 
similar to a more well-studied family of oxidase enzymes - the cytochromes P450 
(CYPs). As a result, research interest in this new FMO gene family was greatly 
enhanced. 4 
Although FMOs possess an acetylated N-terminus which made peptide sequence 
identification difficult initially, these problems were eventually overcome. Today, each 
of the known FMO forms have been shown to be the product of a distinct gene, and 
based on their relative amino acid sequences, have been relegated into five discrete 
families with structural identities between 52-57%. Inter-species FMO orthologs 
displaying 80% or greater identity are assigned to their corresponding family .  In 1994 
a nomenclature system similar to the one established for the CYPs, based on the above 
sequence identity guidelines, was adopted (15). The pig liver FMO form originally 
described by Dr. Dan Ziegler in 1971 was designated FM01. The second FMO, the 
rabbit lung form, has been designated FMO2. The major form in adult human liver has 
been named FMO3 (FMO1 is the predominant form found in human fetal liver). The 
FMO gene product found in high levels in rabbit and rat kidney is FMO4. Finally, an 
FMO isoform found in low levels in many species and tissue types, with unique 
catalytic activity, has been designated FMO5. 
The advances in molecular biology techniques have recently revealed a great 
deal of information about the FMO isoforms. Multiple full-length cDNAs have now 
been reported in the literature that encode FMOs containing approximately 535 amino 
acids, with some isoforms modified with extra amino acids at the C-terminus (1). All 
isoforms studied have shown two highly conserved binding domains, GXGXXG, one 
present at the proposed FAD-binding domain near the N-terminus (between amino acids 
9-14), and the other found at the NADP+-binding domain (between amino acids 186-
196). Both of these domains are required for FMO function (16). The individual 
substrate binding sites for each isoform have yet to be completely elucidated. 5 
SPECIES AND TISSUE DISTRIBUTION 
Although most investigations of FMO species distribution have been limited to 
mammalian systems, a few studies have confirmed FMO-like activities (such as the 
S-oxidation of methimazole) in marine species, such as mussels (17), oysters (18), 
elasmobranchs (19), nurse sharks (20), and in freshwater species, like the rainbow trout 
(21). There are also several reports of flavin-containing oxidases with similar activity 
to FMO found in trypanosomes (22) and Acinetobacter (23). Taken together, these 
studies indicate that FMOs may be present throughout the animal kingdom. 
Within mammalian systems, the highest concentrations of FMO are found in 
liver, and may represent as much as 3% of the total liver microsomal protein in some 
species (24). The lung and kidney also contain considerable amounts of FMO, and 
more than one isoform can be present in any one particular tissue. For example, fetal 
human liver expresses the FMO1 isoform, but in adult human liver the FMO3 isoform 
predominates, and the FMO1 isoform is not found (25, 26). Rabbit liver, which is 
reported to contain four distinct FMO isoforms, expresses the FMO1 isoform at the 
highest levels, and only contains low levels of FMO3 (2). FMO2 is present in rabbit 
lung, kidney and bladder tissues, but is apparently absent from rabbit liver (2). 
FMOs also clearly show a sex-dependence in expression, with distinct 
differences in both activity and the level of expression between males and females 
within a species: For example, FMO activity levels are much higher in male than 
female rats, while female mice elicit higher liver FMO activity than male mice (3, 24). 6 
Female rabbits exhibit higher FMO activity than their male counterparts (3), and during 
pregnancy, FMO2 levels in lung may rise five-fold (27). 
Overall, the flavin-containing monooxygenase enzymes demonstrate a high 
degree of tissue-, species-, developmental-, and sex-specific expression. 
SUBSTRATE SPECIFICITY 
Unlike many other xenobiotic metabolizing enzymes, the flavin-containing 
monooxygenases oxidize an extremely wide variety of chemically and structurally 
diverse substrates. FMOs are capable of oxidizing herbicides and organophosphate 
insecticides such as parathion, aldicarb, demeton and endosulfan. Many industrial 
chemicals are substrates for FMO, such as aniline dyes, hydrazines and diphenyl-
methylphosphine. A wide variety of "recreational drugs" such as amphetamine, 
methamphetamine, nicotine, cocaine, and phencyclidine are excellent substrates for 
FMOs (1-4). FMOs are receiving greater attention in recent years because they 
are also involved in the metabolism of a host of important pharmaceutic agents, such 
as codeine, morphine, cimetidine, imipramine, fenfluramine and tamoxifen. This 
remarkable ability to oxidize such chemically diverse compounds is primarily due to 
the enzyme's ability to generate the relatively stable 4a-hydroperoxyflavin intermediate 
at the active site, in the absence of substrate. This ability of FMO to maintain itself in 
an "activated" state without the binding of substrate is unique among monooxygenases, 7 
and clearly distinguishes this family of oxidases from the CYPs, which require substrate 
binding to initiate oxidation. As a result of this unique catalysis, any soft nucleophile 
that can access the active site will be oxygenated, and this ability to access the active 
site is the most likely determinant of the differential substrate specificities of each of 
the five FMO isoforms. 
Differences in substrate specificity were first reported in 1982, when it was 
noted that microsomal fractions from rabbit liver were able to easily oxidize 
chlorpromazine, imipramine and dimethylaniline, whereas rabbit lung microsomes 
were only able to oxidize dimethylaniline (10-12). In 1984 Williams et al., working 
with purified FMO1 and FMO2 proteins, demonstrated that FMO2 but not FMO1 
could catalyze the oxidation of primary alkylamines (13), and in 1990, structure-
activity assays employing organic sulfur and nitrogen substrates showed that access 
to the hydroperoxyflavin active sites was distinctly different for the FMO1 and 
FMO2 isoforms (28). In 1992 Guo et al. prepared substituted thiocarbamides 
differing in surface area from 91-326 square angstroms (29). With these FMO 
"probes" microsomes from different tissues and species were assayed. Results 
revealed that tissues that accepted "large" thiocarbamides accepted smaller probes 
without exception, and conversely, microsomal samples that were unable to oxidize 
intermediate-sized molecules could never oxidize a larger substrate (Fig. 1.1). 
These studies have allowed estimates to be made of the actual size of the 
substrate binding pockets of various FMO isoforms, and have provided some 
explanations for the observed isoform specificity of various substrates. In general, 8 
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Figure 1.1. Species- and tissue-specific oxidation of selected thiocarbamides. 
Adapted from Ziegler et al., 1991 (29). 
large molecules like chlorpromazine, senecionine or tamoxifen would be expected to 
be oxidized by FMO1 or FMO3, which appear to have larger or more open active site 
conformations, whereas substrates capable of being oxidized by FMO2 would be 
limited to smaller or more narrow molecules like N-octylamine or thiourea, with a 
van der Waals surface area smaller than 180 angstroms (29). 
Despite the diversity of substrates oxidized by FM0s, surprisingly accurate 
predictions can be made about the products resulting from FMO substrate metabolism, 
based on the chemical structure of the parent compound. For example, primary amines 
are oxidized to hydroxylamines, and subsequently to oximes. Secondary amines are 9 
oxidized by FMOs to hydroxylamines, which decompose to nitrones. Tertiary amine 
substrates yield N-oxide metabolites. Sulfur metabolism is equally as predictable, 
with thiols converted to dithiols and disulfides, and sulfides oxidized to sulfoxides 
and sulfones. Phosphine analogs are oxidized by FMOs to yield phosphine oxides (1). 
In spite of the predictability of the products of FMO substrate oxidations, it is 
important to realize that many of the compounds metabolized by FMOs are also 
substrates for other xenobiotic metabolizing enzymes. Therefore, precise predictions 
of a substrate's metabolism must take into consideration the possible contributions of 
other drug-metabolizing enzymes. 
Another striking feature of FMO metabolism is its unique stereoselectivity 
toward chiral substrates. The metabolism of (S)-nicotine by the FMO1 isoform yields 
an approximately 1:1 mixture of cis- and trans-nicotine N'1'-oxides, however FMO2 
metabolism of (S )-nicotine results exclusively in the trans-N-l'oxide (30-32). 
Cimetidine is S-oxidized stereoselectively by hog liver FMO1 to give a (-):(+) 57:43 
enantiomeric mixture, whereas human FMO3 S-oxidizes cimetidine to yield (+):(-) 
84:16 ratio of enantiomers. This stereoselective S-oxidation has been proposed for use 
as a biomarker for diagnostic determinations of the relative contributions of FMO1 and 
FMO3 activity in humans and other animals (33). In addition, Rettie et al., have 
reported promising results in rabbit liver microsomes employing methyl p-tolyl sulfides 
as isoform-selective probes to discriminate between FMO1 and FMO3 metabolism (34). 
Overall, as the list of xenobiotics metabolized by FMO continues to grow, it is highly 
likely that in vivo probes will be employed in ascertaining the contribution of FMO 
isoforms to the metabolism of newly-developed drugs and chemicals. 10 
CATALYTIC MECHANISM  
Flavin-containing monooxygenase was originally referred to as Ziegler's 
enzyme, for Dr. Daniel Ziegler who first discovered this enzyme in the early 1960s 
(35).  Ziegler purified this enzyme to homogeneity from hog liver in 1978 and 
described it as a "unique amine oxidase", capable of N-oxidizing N,N-dimethylaniline 
(36). However, it was soon discovered that "amine oxidase" was too limiting a term, 
as studies ascertained this enzyme's ability to oxidize a variety of chemically-unrelated 
substrates, and the name "mixed function oxidase" was adopted. Kinetic studies that 
followed revealed that most of the Vmax values for good FMO substrates were very 
similar, and that substrate binding had little-to-no effect on turnover rate (37-39). 
Further detailed spectral and kinetic studies with purified FMO1 enzyme from hog liver 
have established the apparent mechanism of the catalytic cycle (Fig. 1.2) (1). 
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Figure 1.2. The catalytic cycle of hog liver FMO1. Adapted from Ziegler et al., 
1991 (1). 11 
The major steps in the catalytic cycle are illustrated in Figure 1.2 (2). In step 1 
the oxidized flavin is quickly reduced by NADPH, to give the reduced flavin, FADH2. 
An important feature of this step is that the NADP± generated from step 1 is apparently 
retained at the active site of the enzyme. In step 2, the reduced flavin rapidly reacts 
with molecular oxygen to generate the active intermediate, the relatively stable 4a-
hydroperoxyflavin. This reactive intermediate has several notable features that are 
important in understanding the enzyme's observed kinetics. It is quite resistant to 
spontaneous decomposition, and is thought to be stabilized, in part, by non-polar amino 
acids in the active site environment. In addition, it is important to note that this reactive 
4a-hydroperoxyflavin intermediate is generated in the absence of substrate binding 
(40). The enzyme has been likened to a "cocked gun", that simply sits in an activated 
state and waits for substrate to appear. Since all of the steps at this point in the catalytic 
cycle occur rapidly, the rate-limiting step(s) in enzyme catalysis are thought to occur 
subsequent to substrate oxidation. And because the energy required for catalysis is 
present and "stored" in the enzyme prior to contact with substrate, it is hypothesized 
that a single point of contact between enzyme and substrate (unlike the specific lock-
and-key conformations required for other similar enzymes) is all that is required for 
catalysis (40). Taken together, these observations provide a partial explanation for both 
the similar Vmax values obtained for good FMO substrates, and for understanding why 
FMO is able to oxidize compounds with such diverse chemical structures (40). From 
an evolutionary standpoint, this strategy makes sense, if the major function of FMO is 
to metabolize dietary components, such as alkaloids, synthesized by plants to ward off 
animal predation. 12 
Step 3 of the catalytic cycle depicts the oxygenation of substrate, which 
proceeds rapidly, producing the oxidized product and generating the 4-hydroxyflavin 
enzyme. 
Steps 4 and 5 of the catalytic cycle are thought to be the rate-limiting steps of 
FMO oxidation, and involve the slow release of H2O and/or NADP+ from the active site, 
with subsequent regeneration of the oxidized flavin moiety. Since NADP+ is a corn-
petetive inhibitor of NADPH, the enzyme's strategy may be to "hang on" to NADP+ 
until substrate oxidation has been accomplished. Also, NADP+ is thought to play a 
"gate-keeper" role at the active site. Catalytic studies have shown that, in the absence 
of NADP+, the reduced flavin form of FMO is allowed to react with molecular oxygen, 
generating substantial amounts of H202 (38, 39). In this scenario, FMO acts merely as 
an efficient "NADPH oxidase", stripping the cell of valuable reducing equivalents, 
while at the same time producing excess amounts of H202 
Despite the absence of a definitive substrate specificity, FMOs still possess 
some means of discriminating between potential substrates. FMOs efficiently exclude 
many negatively charged or zwitterionic soft nucleophiles, such as amino acids or 
glutathione, from the active site. This may be a consequence of the aforementioned 
hydrophobic nature proposed for the substrate binding pocket, as it is generally 
observed that increasing substrate lipophilicity is clearly associated with decreasing 
Km (1).  There are clear indications that secondary factors or other regulatory sites may 
also play a role in FMO oxidations. N-octylamine, while not a substrate for FMO1, 
stimulates the FM01-mediated oxidation of other substrates (36). N-octylamine has 
also been reported to alter the stereos electivity of FM01 S-oxidations (41). 13 
ROLE IN METABOLISM 
Until recently, it has been assumed that most of the oxidations of drugs and 
other xenobiotics was carried out by the CYP family of monooxygenases. Given that 
FMOs and CYPs have relatively the same molecular weight, are both located in the 
endoplasmic reticulum, both require 02 and NADPH, and are active toward many of 
the same substrates, the confusion was understandable. In fact, separating out the 
relative contributions of the two families of monooxygenase enzymes has been a 
difficult task. Today we have a variety of in vitro methods to distinguish FMOs from 
CYPs (reviewed in Table 1.1). 
FMOs catalyze the N-oxidation of primary, secondary and tertiary amines. 
They carry out of the S-oxidation of thiols, thiones, thioethers, sulfides, and thioamides. 
Soft nucleophilic iodides, phosphines, selenides and boron-containing compounds 
are also known substrates for FMO (1). Researchers have speculated that FMOs (and 
CYPs) may have evolved in mammals to oxidize alkaloids, glucosinolates, and a host 
of other soft nucleophilic compounds produced during evolution in plant-animal 
warfare (42-45). 
The endogenous function of FMO in mammalian metabolism has yet to be 
determined, but FMOs are known to oxidize several physiologically relevant substrates. 
Cysteamine, which may be implicated in the folding of proteins via formation of 
disulfide bridges, is efficiently S-oxidized by FMO to the disulfide cystamine. The 
cysteamine/cystamine ratio may act as a "third messenger" in the cell, regulating 14 
oxidation/reduction potential (1, 46, 47). Trimethylamine (TMA), a low molecular 
weight tertiary amine with an extremely unpleasant odor, is efficiently converted to 
the odorless trimethylamine N-oxide (TMAO) by FMO (48). An inherited defect of 
TMA catabolism, trimethylaminuria (also known as fish-odor syndrome), has been 
associated with lack of expression of FMO3, the major FMO expressed in human liver 
(49-53).  Patients suffering from this disease excrete volatile unoxidized TMA in their 
sweat and breath, and smell of rotting fish. Other than dietary choline restriction, no 
treatments are known at this time. Methionine, a sulfur-containing amino acid, is 
converted to methionine sulfoxide by FMO1, FMO2 and FMO3. Althought the Km 
for this reaction is quite high, it may represent a significant catabolic pathway in 
patients suffering from inborn errors in methionine transsulfuration (54). 
In the overwhelming majority of cases, FMO oxidations represent detoxification 
pathways, where the compound of interest is usually rendered more water-soluble, and 
is easily excreted. For example, pyrrolizidine alkaloids are metabolized by both FMOs 
and CYPs. While FMO metabolism of these alkaloids results in the formation of a 
harmless N-oxide, CYPs activate these alkaloids to toxic electrophilic pyrroles (55, 56). 
Tamoxifen is N-oxidized by FMO to give a more polar metabolite that is easily 
excreted, but CYP-mediated demethylation of this anti-cancer drug leads to a toxic 
congener (57). 
However, not all oxidation of xenobiotics by FMOs result in detoxification, 
and activation of some compounds by FMOs to more toxic, even carcinogenic 
metabolites, has been demonstrated. For example, 2-acetylaminofluorene, initially 15 
developed as an insecticide, undergoes N-hydroxylation of the acetylamino group to 
give a hydroxyarylamine. This intermediate is then esterified by acetylases or 
sulfotransferases to form an electrophilic arylnitrenium ion, leading to DNA binding 
and adduct formation (58). Substituted hydrazines, a diverse class of chemicals used as 
herbicides, reducing agents and rocket fuels, undergo similar N-hydroxylation to yield 
highly reactive species (6, 59). FMO efficiently S-oxidizes 2-mercaptoimidazoles to 
sulfenic acids, and finally to sulfinic acids (3, 60-61). However, the sulfenic acid 
intermediate can readily form thiol adducts. These adducts can act as disulfide 
exchange sites for net thiol oxidation and substrate regeneration (62). This futile 
cycling can deplete cellular glutathione and NADPH levels, leaving the cell vulnerable 
to toxic insults by other chemicals (1). A similar futile cycling mechanism is seen in 
the FMO-mediated oxidation of selenium-containing compounds. FMOs catalyze 
oxidation of selenides and selenols to selenoxides, thiol-reactive metabolites capable 
of the same glutatione depletion as the above-described sulfinic acids (63). These 
and other studies have led to a heightened interest in the role of FMOs in the overall 
metabolism of drugs and xenobiotics, and will undoubtedly remain an important area 
of research in the future. 
REGULATION OF EXPRESSION 
FMOs do not appear be to be highly inducible by TCDD, phenobarbital, or any 
of the other classic CYP inducers. However, it has recently been proposed that FMOs 
may indeed be inducible by phytochemicals or other xenobiotics in the diet. Kaderlik 16 
et al. showed that rats maintained on semi-synthetic diets demonstrate lower in vivo 
expression of FMOs than animals fed chow diets (64), but no clear mechanism has 
been offered to explain this observation. FMO levels are clearly influenced by age, 
sex and estrus cycle (65). FMOs are induced during pregnancy (27, 66), and maternal 
rabbit lung shows a five-fold increase in FMO during gestation, with the highest 
induction corresponding to peak plasma cortisol and progesterone levels (66). 
Administration of glucocorticoids and steroid hormones to non-pregnant animals 
demonstrated frank induction of FMO in rabbit lung (67). Experiments with 
gonadectomized animals demonstrate that FMOs are regulated hormonally (68, 69), 
and that this regulation is tissue-dependent. While FMOs demonstrate clear induction 
with glucocorticoids and steroid hormones, no true inhibitors of FMO expression are 
known. 
Studies were undertaken to establish the tissue-specific patterns of expression 
of flavin-containing monooxygenase isoforms during fetal and neonatal development. 
Results indicate that FMOs can play a significant role in the potential for target organ 
toxicity during fetal and neonatal exposure scenarios. Also investigated was the role 
of dietary components in modulating FMO expression in both adults, and in neonates. 
These studies identify the first known in vivo inhibitor of FMO expression, not 
associated with a dietary deficiency or disease state. 17 
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DEVELOPMENTAL REGULATION OF FLAVIN-CONTAINING  
MONOOXYGENASE FORM 1 IN THE LIVER AND KIDNEY  
OF FETAL AND NEONATAL RABBIT  
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ABSTRACT 
Flavin-containing monooxygenases (FMOs) comprise a multi-gene family 
of monooxygenase enzymes, and catalyze the oxidation of soft nucleophilic sulfur-, 
nitrogen-, and phosphorus-containing xenobiotics. Previous studies have shown FMO 
to be regulated developmentally, and by administration of steroid hormones. This study 
examined the development of flavin-containing monooxygenase (FMO) form 1 in the 
liver and kidney of fetal and neonatal rabbits, from the beginning of the 3rd trimester 
through three weeks of age, by utilizing isoform-specific antibodies and substrates. 
FMO protein levels were analyzed by western blotting. Catalytic activities were 
measured by following the S-oxidation of diphenylthiourea. In fetal liver a gradual rise 
in FMO1 protein was observed throughout the fetal period. After parturition, FMO1 
levels continued to increase through day 21 post-partum, the last time point measured. 
In fetal kidney FMO1 protein levels remained low throughout the gestational period, 
and were measured at approximately 35% of FMO1 liver levels by post-partum day 21. 
The early developmental appearance of FMO1 , and the substantial levels of FMO1 
present in early neonatal liver, suggests an important role in the metabolism of 
xenobiotics through transplacental or lactational exposures. 26 
INTRODUCTION 
Flavin monooxygenases (FMOs) are located in the endoplasmic reticulum of 
most mammalian cells, and catalyze the NADPH-dependent oxidation of a wide variety 
of compounds containing nitrogen, sulfur, phosphorus and selenium atoms (1-3). This 
family of phase I enzymes contains five members, each encoded by a distinct gene 
(4, 5). These enzymes, unlike the cytochromes P-450 (CYPs), display a broad substrate 
specificity, and play an important role in the metabolism of many drugs, pesticides and 
other xenobiotic compounds (1). Although FMO isoforms are widely distributed in 
mammalian tissues, little is known of their role in human metabolism. FMOs are 
known to metabolize several endogenous substrates, including cysteamine, methionine 
and trimethylamine (3), and it has been hypothesized that FMOs evolved to metabolize 
alkaloids and other plant materials in the mammalian diet (6, 7). 
Unlike the CYPs, FMOs have been shown to be quite refractory to dietary or 
chemical induction. However, FMOs do appear to be developmentally regulated, 
presumably through the action of steroid hormones (8, 9). FMO induction by gluco-
corticoids has been demonstrated (10), but no inhibitors of FMO expression, not 
associated with a disease state, are known. In most cases, FMO oxidation of drugs and 
xenobiotics represents a detoxication pathway, however a few instances of bioactivation 
of xenobiotics is known (3). 
This study examined the relationships between protein levels and catalytic 
activity of FMO1, the predominant form of FMO found in rabbit liver and kidney, from 
day 25 of gestation through 21 days post-partum. FMO protein levels were analyzed by 27 
western blotting. Catalytic activities were measured by the S-oxidation of the 
substituted thiocarbamide, diphenylthiourea. 
Analysis of liver tissue showed a gradual rise in FMO1 levels in fetal liver from 
day 25 of gestation until parturition. Following parturition FMO1 levels continued to 
rise until the last time point measured, 21 days post-partum (weaning). At this time 
FMO levels had reached about 70% of normal adult liver levels. A fairly high degree of 
inter-individual variability was found in 8-day and 21-day post-partum kit liver FMO 
levels. 
FMO1 levels in fetal kidney were found to be quite low at the first time point 
measured, day 28 of gestation (25-day fetal liver samples were lost prior to analysis). 
FMO1 levels continued to remain low throughout the gestational period, but began 
to rise at day 8 post-partum. By 21 days post-partum, the last time point measured, 
FMO1 levels in neonatal kidney had reached about 50% of adult kidney FMO1 levels. 
The early developmental appearance of FMO1 in rabbit liver, and to a lesser 
extent in rabbit kidney, suggests a significant role in the metabolism, and subsequent 
target organ toxicity, of xenobiotic compounds, for both the fetus and the neonate, 
through transplacental and/or lactational exposures. 28 
MATERIALS AND METHODS  
Chemicals 
Glucose-6-phosphate, glucose-6-phosphate dehydrogenase, NADP+, catalase, 
acetylthiocholine hydrochloride, benzylimidazole, and 5,5-dithiobis-(2-nitrobenzoate) 
were purchased from Sigma Chemical Co. (St. Louis, MO). Highly purified diphenyl-
thiourea (DPTU) was a generous gift from Dr. Daniel Ziegler (University of Texas at 
Austin). 
Animals 
Timed-pregnant New Zealand white rabbits were obtained from the Rabbit 
Research Institute at Oregon State University, and housed individually in birthing 
cages in the Laboratory Animal Resource Center. The rabbits were maintained on a 
12-hr day-night cycle, and rabbit chow and water were provided ad libitum. Three 
rabbits were euthanized by CO2 asphyxiation on days 25, 28, and 31 days of gestation, 
and 1, 8 and 21 days post-partum. The liver and kidneys were removed, quick-frozen 
in liquid nitrogen, and stored at -80°C until analysis. Due to the small tissue size, fetal 
tissues were pooled from each litter, as were the tissues from 1 day-old kits. The liver 
and kidney tissues from 8 and 21-day old kits were analyzed separately. 
Microsome Preparation 
Fetal and neonatal liver tissues were thawed rapidly on ice in four volumes of 
homogenization buffer (0.1 M potassium phosphate [pH 7.25], containing 0.15 M KC1, 
1 mM EDTA, 0.1 mM phenylmethylsulfonylfluoride, 1 mM dithiothreitol, and 20 pM 29 
butylated hydroxytoluene) and homogenized with a polytron (Brinkman, Westbury, 
NY). Microsomes were then prepared by differential centrifugation as described by 
Guengerich (11). Microsomal protein concentrations were determined by the method 
of Lowry et al. (12) with bovine serum albumin as the standard. 
FMO Catalytic Activity 
FMO1 activity in microsomal tissues was assayed at 37°C by a modification of 
the method of Guo and Ziegler (13), which followed the DPTU-dependent oxidation 
of thiocholine, utilizing the reaction conditions previously described by Larsen-Su and 
Williams (14). Initial reaction conditions were as follows: 0.1 M potassium phosphate 
(pH 7.5), 0.4 mM EDTA, 0.25 mM NADP+, 2.5 mM glucose-6-phosphate, 100 µM 
DPTU, 100 U catalase, and 2 mM benzylimidazole, with glucose-6-phosphate dehydro-
genase added in sufficient amount to reduce 1 pmol NADP+/min.ml. Total final assay 
volume was 2.5 ml. 
Western Blots 
Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) (15) and transferred electrophoretically to nitrocellulose (16). 
The reagents and equipment employed in SDS-PAGE were purchased from Bio-Rad 
(Richmond, CA). Western blotting was performed utilizing a semi-dry transfer cell. 
FMO 1 proteins were visualized by staining with primary antibody raised in rabbits 
against pig liver FMO1, and HRP-conjugated goat-anti-rabbit IgG as the secondary 
antibody, with purified pig liver FMO1 as the standard. Both the primary antibody and 
the purified FMO1 standard were a generous gift from Dr. Daniel M. Ziegler, 30 
University of Texas at Austin. A standard curve of purified standards was utilized for 
quantitation of each individual blot. Quantitation was performed by visualization with 
an ECL chemiluminescence kit from Amersham Corp. (Arlington Heights, IL). Densi-
tometry analysis of autoradiograms was accomplished using an HP ScanJet IIcx/T 
flatbed scanner, employing NIH Image version 1.54 software (public domain, Wayne 
Rasband, NIH; available from the internet). 
RESULTS 
The catalytic activity of fetal and neonatal liver FMO1 was followed by 
measuring the S-oxidation of diphenylthiourea (Fig. 2.1) FM01 catalytic activity 
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Figure 2.1. Catalytic activity of rabbit liver FMO1. Catalytic activity was assayed 
by following the S-oxidation of diphenylthiourea spectrophotometrically at 412 nm. 
FMO1 activity levels in rabbit liver initally were low, but gradually rose to 70% of that 
of the adult. The data represents the mean off standard error of three activity 
determinations for each sample. 32 
and neonatal rabbit liver microsomes at the first time point measured, gestational 
day 25. FMO1 protein levels were low at this time, but continued to rise steadily 
throughout gestation. After parturition FMO1 protein levels from neonatal liver 
continued to rise, and by 21 days post-partum, the last time point measured, FMO1 
levels were found to be about 70% of normal adult liver levels. 
FMO1 activity levels were also assayed in fetal and neonatal kit kidney tissues 
by the S-oxidation of diphenylthiourea (Fig. 2.3). (The pooled fetal tissue samples from 
day 25 of gestation were lost prior to analysis, so no results are shown for this time 
point.) 
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Figure 2.3. Catalytic activity of fetal and kit kidney FMO1. FMO1 activity, 
assayed as the S-oxidation of diphenylthiourea, was measured in fetal and neonatal 
kidney microsomes. The data represent the mean off standard error of three activity 
determinations for each sample. 33 
FMO1 activity levels were not detected in fetal rabbit kidney microsomes, or 
in day 1 post-partum microsomes. However, activity was seen at 8 days post-partum, 
and continued to increase through the last time point measured, day 21 post-partum, 
where activity levels were determined to be about 25% of adult levels. 
Western blot analysis of FMO1 rabbit fetal and neonatal kidney microsomes 
was also performed. Protein was detected with antibody to pig liver FMO1, then 
quantitated by densitometry of western blots. Results are shown in Fig. 2.4. 
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Figure 2.4. FMO1 protein levels in fetal and neonatal rabbit kidney. FMO1 kidney 
protein levels were determined by densitometry of western blots probed with antibody 
to pig liver FM01 protein. Each data point represents the mean off standard error for 
three animals. 34 
In fetal kidney, FMO1 protein was barely detectable at day 28 of gestation, 
the first time point measured. FMO1 protein levels remained low, until 8 days post-
partum, where they had increased approximately 4-fold over day 1 post-partum 
measurements. By 21 days post-partum, the last time point measured, FMO1 protein 
levels in neonatal kidney were continuing to increase, and were reported as 
approximately 33% of adult kidney FMO1 levels. Overall, FMO1 protein levels, as 
determined by western blot, closely mirrored the pattern of FMO1 activity demonstrated 
by diphenlythiourea assay in both liver and kidney microsomes. 
DISCUSSION 
It has been reported that all five FMO isoforms are present in adult rabbit liver 
(4, 5), and that FMO1 is the predominant FMO isoform expressed (3). In adult rabbit 
kidney, two FMO isoforms are known, FMO1 and FMO2, but FMO1 is the pre-
dominant isoform expressed. While FMO1 shares approximately 56% primary 
sequence identity with other FMO isoforms, it can be distinguished immunochemically, 
and by its unique substrate specificity (5). We have demonstrated the expression of 
FMO1 protein and activity during fetal and neonatal development in rabbit liver and 
kidney. In fetal liver, FMO1 levels are low in late gestation. However, before the age 
of weaning (21 days post- partum) neonatal rabbits are already expressing substantial 
levels of FMO1 protein and activity in the liver. FMO1 levels in the fetal kidney are 35 
very low, barely detectable by western blotting, and no associated activity was 
determined. However, by day 21 of gestation, FM01 protein is expressed at detectable 
levels in neonatal kidney, at about 33% of adult levels. 
Presently, developmental regulation of fetal and neonatal xenobiotic metabol-
izing enzymes remains an under-studied arena. For some time the traditional dogma 
has been that fetal and neonatal systems possess very limited innate xenobiotic 
metabolic capabilities, and it was assumed that chemicals required both activation by 
the metabolic machinery of the mother, and the additional ability to tranverse the 
placenta or be transferred lactationally, before representing a threat to the fetus or 
neonate. Researchers now acknowledge that fetal/neonatal systems have the intrinsic 
ability to effect metabolic transformations. Detailed knowledge of these xenobiotic 
metabolizing systems is essential to future risk assessment and drug-design strategies. 36 
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ABSTRACT 
Mammalian flavin-containing monooxygenase functions in the oxygenation of 
numerous xenobiotics containing a soft nucleophile, usually a nitrogen or sulfur. A 
total of five distinct flavin monooxygenase (FMO) isoforms are expressed in mammals. 
Individual isoforms are expressed in a sex-, age-, and tissue-specific fashion. In this 
study, we document the early developmental appearance of the major isoform in rabbit 
lung, FMO2. FMO2 catalytic activity, as well as protein and mRNA are not only 
present in fetal and neonatal lung, but in some instances approach levels found in the 
adult. The expression pattern of FMO2 is similar to that of the two major constitutive 
cytochromes P450 found in rabbit lung, 2B4 and 4B1. The early developmental 
appearance of these monooxygenases indicate an important role in the protection of the 
fetus and neonate against toxic insult from foreign chemicals. 40 
INTRODUCTION  
Mammalian flavin-containing monooxygenase (FMO, EC1.14.13.8) oxygenates 
a great number of structurally diverse xenobiotics which have the common feature of 
containing a soft nucleophile (1-3). FMO has a number of characteristics in common 
with the cytochrome P450 (CYP) monooxygenase system, including molecular weight, 
localization within the endoplasmic reticulum, highest expression in liver, a requirement 
for NADPH and 02, existence of multiple isoenzymes, and developmental- and tissue-
specific expression (1-3). In contrast, while these two enzyme systems share a number 
of common substrates (1-5), the products (with the exception of secondary amines) are 
usually different. Another marked difference between FMOs and CYPs is that although 
CYPs are inducible by exposure to xenobiotics, (e.g., TCDD induction of CYP1A1, 
phenobarbital induction of CYP2B, ethanol induction of CYP2E1, and erythromycin 
induction of CYP3A (6), FMO induction by foreign compounds has not been 
demonstrated. 
FMO, like CYP, exists as a multi-gene family, but with only a single member 
per family (five families total) designated FMOs 1-5 (7, 8). The major form expressed 
in lung is FMO2. Orthologs of FMO2 have been sequenced from rabbit (9), guinea 
pig (10), and recently, Rhesus monkey (11). Previous work from this, and other 
laboratories, has documented that FMO2 levels are regulated in a developmental- and 
tissue-specific manner, possibly through steroid hormone control (12-19). Recently, the 
5'-flanking region sequence for rabbit FMO2 has been obtained independently from 
genomic clones by both our collaborator, Dr. R. N. Hines, and another laboratory (21). 41 
In this paper we describe the ontogenesis of FMO2 in lung of fetal and neonatal 
rabbits, and compare the pattern with the major constitutive isoenzymes of CYP. 
Examination of catalytic activity, protein and mRNA document that FMO2 can be 
expressed at relatively high levels in fetal lung as early as the 25th day of gestation. In 
general, the developmental pattern is similar to the CYP monooxygenase system, with a 
couple of notable exceptions. The isoform expression of both monooxygenase systems 
displays a large amount of variation between litters, as well as inter-individual 
variability within the same litter, which is not surprising given the relative degree of 
outbreeding among New Zealand white rabbits. The early developmental appearance of 
these xenobiotic-metabolizing enzymes would suggest an important role in the 
protection of fetal and neonatal animals against the toxic effects of foreign compounds. 42 
MATERIALS AND METHODS 
Animals 
Timed-pregnant New Zealand white rabbits were obtained from the Rabbit 
Research Institute at Oregon State University, and housed individually in birthing cages 
in the Laboratory Animal Resource Center. The rabbits were maintained on a 12-hr 
day-night cycle, and chow and water were provided ad libitum. Three rabbits were 
euthanized by CO2 asphyxiation on days 25, 28, and 31 days gestation, and 1, 8 and 21 
days post-partum. A small portion of the fetal or neonatal lung was rapidly quick 
frozen by smashing between two blocks of dry ice and then transferring into liquid 
nitrogen. The remaining tissue was then removed and also frozen in liquid nitrogen, 
and stored at -80°C until analysis. Due to the small tissue size, fetal lungs were pooled 
from each litter, as were the lungs from 1 day-old kits. The lungs from 8 and 21-day 
old kits were analyzed separately. 
Microsome Preparation 
Fetal and neonatal lung tissues were thawed in four volumes of homogenization 
buffer (0.1 M potassium phosphate [pH 7.25], containing 0.15 M KC1, 1 mM EDTA, 
0.1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, and 2012M butylated 
hydroxytoluene) and homogenized with a polytron (Brinkmann, Westbury, NY). 
Microsomes were then prepared by differential centrifugation as described by 
Guengerich (22). Microsomal protein concentrations were determined by the method 
of Lowry et al. (23), with bovine serum albumin as the standard. 43 
FMO Catalytic Activity 
FMO2 activity in microsomal tissues was assayed at 37°C by a modification of 
the method of Guo and Ziegler (24), which follows the thiourea-dependent oxidation of 
thiocholine, utilizing the reaction conditions described by Larsen-Su and Williams (25). 
Thiourea was purchased from Aldrich Chemical Co. (Milwaukee, WI). Glucose -6-
phosphate, glucose-6-phosphate dehydrogenase, NADP+, catalase, acetylthiocholine 
hydrochloride, benzylimidazole, and 5,5-dithiobis-(2-nitrobenzoate) were purchased 
from Sigma Chemical Co. (St. Louis, MO). Initial reaction conditions were as follows: 
0.1 M potassium phosphate (pH 7.5), 0.4 mM EDTA, 0.25 mM NADP+, 2.5 mM 
glucose-6-phosphate, 100 IIM thiocholine, 100 U catalase, and 2 mM benzylimidazole, 
with glucose-6-phosphate dehydrogenase added in sufficient amount to reduce 1 [tmol 
NADP+/minml. Total final assay volume was 2.5 ml. 
Western Blots 
Microsomal proteins were resolved by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) (26) and transferred electrophoretically to 
nitrocellulose (27). The reagents and equipment employed in SDS-PAGE were 
purchased from Bio-Rad (Richmond, CA). Western blotting was performed utilizing a 
semi-dry transfer cell and FMO2, CYP2B4 and CYP4B1 proteins were visualized by 
staining with primary antibody raised in guinea pig against each protein, and HRP-
conjugated goat anti-guinea pig IgG as the secondary antibody, with purified FMO2, 
CYP2B4 or CYP4B1 employed as standards. Quantification was performed by 
visualization with an ECL chemiluminescence kit from Amersham Corp. (Arlington 
Heights, IL) followed by densitometry of autoradiograms using an HP Scan Jet IIcx/T 
flatbed scanner, employing NIH Image version 1.54 software (public domain, Wayne 44 
Rasband, NIH; available from the internet). A standard curve of purified standard was 
utilized for quantification of each individual blot. 
Total RNA Isolation 
Total RNA was isolated from rabbit lung by the method of Chomczynski and 
Sacchi (28) using TriReagent (Molecular Research Center, Cincinnati, OH). RNA was 
then stored at -80°C until analysis. RNA concentration was estimated from the A260. 
The integrity of the RNA was confirmed by electrophoretic separation of 10 [t.g RNA 
on formaldehyde-agarose gels and examining the 18S and 28S rRNA bands. 
Probes for RNA Detection 
All cDNA probes used in this study were derived from rabbit. The CYP2B4 
(provided by S. Wrighton, Eli Lilly, Indianapolis, IN) and CYP4B1 (provided by R. 
Philpot, NIEHS, Research Triangle Park, NC) inserts were cut from their respective 
plasmids with EcoRI, in each case yielding the full-length cDNA. cDNA clones 
correspond to previously reported sequences (29). A full-length (1641 bp) FMO2 
cDNA clone obtained from the laboratory of Dr. R. N. Hines was cut with EcoR11 Avr11 
yielding an 1142 by subfragment from the 5' region of the FMO2 clone. Inserts were 
isolated and purified as described elsewhere (30). Isolated cDNA fragments were 
random-primed labeled (31) with digoxigenin-11-dUTP, and were quantified according 
to the manufacturers' instructions (Boehringer-Mannheim, Indianapolis, IN). Probe 
specificity was determined by hybridizing the probes to dot blots prepared with all of 
the cDNAs of interest. 45 
Oligonucleotide Probe for Normalization 
A 15-mer anti-sense oligonucleotide (obtained from S. Giovannoni, Oregon 
State University, Corvallis, OR) universally complimentary to 16S rRNA isolated from 
eubacteria, archaebacteria, and eukaryotes (32) was 3'-end labeled with digoxigenin-
ddUTP and was quantified according to the manufacturers' instructions (Boehringer-
Mannheim, Indianapolis, IN). The probe was used at a concentration of 5 pmol labeled 
to 100 pmol unlabeled oligonucleotide per ml of hybridization buffer to normalize RNA 
concentrations on blots. 
RNA Blotting, Detection and Quantitation 
Total RNA (10 p,g) was blotted on Hybond N+ (Amersham, Arlington Heights, 
IL) nylon membranes with a slot blotting manifold, and was fixed by UV-cross linking 
and baking. RNA isolated from an adult male was blotted at varying concentrations on 
each membrane. Membranes were prepared in quadruplicate, one membrane for each 
probe. Hybridization and detection of mRNA levels was performed by the method of 
Engler-Blum et al., (33) with the modifications reported by Krueger and Williams (30). 
Chemiluminescence emissions were measured by densitometry of Hyperfilm MP 
(Amersham, Arlington Heights, IL) exposed to the blots, using the same equipment and 
software as for the western blots. Adult male FMO2 RNA was used in combination 
with 1406R to normalize density for variation in RNA sample loading, and regression 
analysis was used with each probe to fit density vs. RNA concentration, since RNA 
standards for the probes were not available. 46 
RESULTS  
Fetal Lung FMO2 catalytic activity (Fig. 3.1), as determined by thiourea S-
oxidation, was found to be quite high at gestational day 25 (the first measured time 
point), and peaked at day 31, just prior to parturition. With the exception of gestation 
day 28, where FMO2 activity levels were very low, fetal lung FMO2 activity 
approached that of the adult (3.0-3.5 nmoles/min/mg protein) (2). At day 1 following 
parturition, neonatal lung FMO2 activity levels plummeted, dropping to about 15% of 
their gestational day 31 levels. FMO2 lung activity assayed at 8 days post-partum 
showed approximately a 2-fold increase in activity compared with day 1 post-partum 
levels, and by 21 days post-partum, FMO2 lung activity had recovered to about 70% 
of adult levels. 
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Figure 3.1. FMO2 activity in fetal and neonatal rabbit lung. FMO2 catalytic 
activity was determined in fetal and neonatal rabbit lung microsomes, by following 
the S-oxidation of thiourea from 25 days gestation through 21 days post-partum. 
Each data point represents the mean of ± standard error for three animals. 47 
Appearance of FMO2 protein in fetal and neonatal rabbit lung mirrored the 
pattern of FMO2 activity previously described (Fig. 3.2). FMO2 protein levels were 
found to be highest at day 31, just prior to parturition. At birth FMO2 protein levels fell 
dramatically, with gradual recovery to about 60% of adult levels by day 21 post-partum, 
the last time point measured. 
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Figure 3.2. FMO2 protein levels in fetal and neonatal rabbit lung. Protein levels 
were obtained following densitometry of immunoblots probed with antibody to rabbit 
lung FMO2. Each data point represents the mean of ± standard error for three animals. 
The pattern of expression of FMO2 mRNA in fetal and neonatal lung was found 
to be similar to both the FMO2 fetal/neonatal protein and catalytic activity expression 
(Fig. 3.3). Fetal FMO2 mRNA levels were highest at day 31 of gestation, just before 
birth. Neonatal FMO2 mRNA levels declined slightly at birth, but were measured to be 48 
approximately 75% of adult levels by day 21, the last time point measured. It should 
be noted that a high degree of inter-individual variability existed in the FMO2 mRNA 
levels in both 8 and 21 days post-partum. As also seen in both protein and activity 
assays, the FMO2 mRNA levels were extremely low at day 28 of gestation. 
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Figure 3.3. FMO2 mRNA levels in fetal and neonatal rabbit lung. FMO2 mRNA 
levels are reported as a percent of the level detected in adult male lung RNA with a 
FMO2 cDNA probe. All results are from 10 p.g total RNA reported as mean mRNA 
levels detected from fetal tissue pools from each dam (n = 3), the mean of kit tissue 
pools from each dam at 1 day post-partum (n = 3), or the mean of individual kits from 8 
and 21 days post-partum (7 and 21 samples respectively). ND = not detected. 
CYP2B4 protein levels measured in lung (Fig. 3.4A) were consistent with 
CYP2B4 mRNA levels (Fig 3.5A). CYP4B1 protein expression was found to be 49 
A  
300  
200  
Parturition  
100  
11.1c:.;.-.7,21111 
25  28  31  1PP  8p  21pp  
Fetal and Kit Age (days)  
B 
250  
200  
Parturition  
150  
100  
50  
0  
25  28  31  1PP  Opp  21iip  
Fetal and Kit Age (days)  
Figure 3.4. CYP2B4 and CYP4B1 protein levels in fetal and neonatal rabbit lung. 
Protein levels were obtained followed densitometry of immunoblots probed with 
antibody to CYP2B4 (Fig. A, top) or CYP4B1 (Fig. B, bottom). Each data point 
represents the mean of ± standard error for three animals. 
highest at day 25 of gestation (Fig. 3.4B), and was again consistent with CYP4B1 
mRNAlevels. At parturition, CY2B4 mRNA dropped to undetectable levels, then 50 
gradually recovered through post-partum day 21 (Fig. 3.5B). Consistent with protein 
level determinations, there was almost total ablation of of CYP2B4 and CYP4B1 
mRNA. 
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Figure 3.5. CYP2B4 and CYP4B1 mRNA levels in fetal and neonatal rabbit lung. 
CYP2B4 (Fig A, top) and CYP4B1 (Fig. B, bottom) mRNA levels are reported as a 
percent of the level detected in adult male lung RNA with full-length cDNA probes. 
All results are from 10 lig total RNA expressed as mean mRNA levels detected from 
samples (as described in Fig. 3.3). ND = not detected. 51 
Overall, the developmental pattern of fetal/neonatal FMO2 (Fig. 3.2) in rabbit 
lung is consistent with that of CYP2B4, the major constitutive CYP found in lung 
(Fig. 3.4). The other major CYP in adult rabbit lung, CYP4B1, demonstrates a slightly 
different pattern from both FMO2 or CYP2B4. This CYP elicited the highest protein 
levels at the first time point measured (gestation day 25), then, with the exception of 
day 28, gradually declined to very low levels by 8 days post-partum. Recovery to 
approximately 70% of adult CYP4B1 levels was observed by post-partum day 21 
(Fig. 3.4). 
DISCUSSION 
In this study we characterize the developmental expression of FMO2, the 
major FMO isoform present in rabbit lung. FMO2 levels in fetal lung are high at late 
gestation (with the exception of day 28). At parturition FMO2 levels fall dramatically, 
followed by significant recovery by 21 days post-partum, the last time point measured 
The profound depression of FMO2 protein levels and enzymatic activity docu-
mented at day 28 of gestation, although surprising, was in agreement with measured 
mRNA levels. This loss of FMO2 expression was found to coincide with a unique 
physiological phenomenon in pregnant rabbits, known as hair-pulling (34). In 
preparation for parturition (day 31), female rabbits experience a sudden release of 
oxytocin from the pituitary, timed between gestational day 27-28 that results in, among 
other things, marked loosening of the female's hair. This loosened hair is then easily 52 
pulled out by the female, which she subsequently uses to line her nest. This large and 
transient release of oxytocin may be involved in the down-regulation of the fetal FMO2, 
CYP 2B4 and CYP 4B1 protein and mRNA levels observed in this study, although to 
our knowledge, no findings concerning oxytocin regulation of FMO have appeared in 
the literature. 
FMO2 and CYP 2B4 protein and mRNA levels in fetal lung were found to 
correspond to previously reported peak cortisol and progesterone levels in maternal 
plasma (19). It has been observed previously by our laboratories and others (12, 14, 16, 
19) that FMO2 expression in adult rabbit lung appears to be stimulated by progesterone 
or glucocorticoids. The rabbit fetal lung possesses the cellular machinery for such a 
response, as glucocorticoid receptors are present and function in lung maturation (35-
37). An earlier study by Devereux and Fouts (38) had documented the induction of 
N,N-dimethylaniline N-oxidase activity in fetal lungs following treatment of the mother 
with dexamethasone. 
Loss of neonatal FMO2 protein, enzymatic activity and mRNA immediately 
after parturition most probably reflects a loss of influence of the mother's hormonal 
milieu. Overall, the consistent association of enzymatic activity, protein levels and 
mRNA levels support the hypothesis of regulation of FMO at the transcriptional 
level. Wyatt et al. (21) reported that the 5'-flanking region of the rabbit FMO2 gene 
contains three putative glucocorticoid response elements (GREs). Dr. Ron Hines 53 
results, however, did not find such GRE sites in the rabbit FMO2 5'-flanking region, 
but provided evidence that the transcription may be regulated through PEA3-Ets 
(polyomavirus enhancer activator 3, E-26 transformation-specific) and TTF-1 
(thyroid transcription factor 1) (20), a finding that would be consistent with the 
tissue-specific expression of FMO2. 
In relating mRNA, protein and catalytic measurements at any given time point, 
it should be acknowledged that, to date, the half-life of mRNA or protein for any FMO 
is unknown. 
These results show that FMOs are present in active form, even in early 
gestation. It is this early developmental expression that suggests that FMOs can play a 
significant role in the detoxication and subsequent target organ toxicity of many foreign 
compounds, both from in situ metabolic activation, and through transplacental and/or 
lactational exposures. Detailed knowledge of the tissue-specific composition of FMO 
isoforms, as well as their unique substrate specificities, coupled with elucidation of the 
regulatory regions of the individual genes, is of paramount importance in assessing fetal 
and neonatal exposure/risk scenarios, as well as predicting the metabolism and 
clearance of drugs and other xenobiotics. 54 
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ABSTRACT 
Indole-3-carbinol (13 C), a naturally-occurring component of cruciferous 
vegetables, has been shown to be an effective cancer chemopreventative agent in a 
number of animal models, and is currently being evaluated in human clinical trials. 
One proposed mechanism of action for I3C involves binding of 13C acid condensation 
products (formed in the stomach) to the Ah receptor, with resultant induction of both 
Phase I and Phase II enzymes. We have previously shown that dietary administration 
of I3C to male Fischer 344 rats markedly induces hepatic levels of CYP1A1, and to 
a lesser degree CYP1A2, CYP2B1/2, and CYP3A1/2. We now report that such treat-
ment concurrently inhibits both the expression of flavin-containing monooxygenase 
(FMO) form 1, as well as FMO activities in rat liver and intestine. This inhibition 
demonstrates both a time and dose dependency, resulting in an 8-fold reduction in 
expression of FM01 in liver, and almost total ablation of FM01 in intestinal tissues 
at the highest dietary I3C levels examined. There are many examples of xenobiotics 
which are metabolized by both the CYP and FMO monooxygenase systems. In many 
cases these enzyme systems produce different metabolites, which often have strikingly 
disparate toxicological and/or therapeutic properties. Therefore, the marked shift in 
the ratio of FMO/CYP levels in the livers (and other tissues) of rats fed 13C may result 
in significant alterations in the metabolism, disposition and toxicity of xenobiotics. 
Testing for a similar phenomenon in humans would seem advisable prior to wide-
spread I3C administration. 60 
INTRODUCTION 
Indole-3-carbinol (I3C), a plant alkaloid found in significant concentrations in 
brussels sprouts, broccoli, and other cruciferous vegetables, provides chemoprevention 
against the development of both spontaneous and chemically-induced cancers in a 
number of animal models (1-3). These findings have encouraged the undertaking of 
human clinical trials for the chemoprevention of breast cancer, endometrial cancer, and 
other estrogen-related cancers (4-6). A cautionary note, however, has recently been 
raised by the finding that, under certain experimental conditions, I3C can elicit 
promotional effects leading to increases in both tumor incidence and formation of 
preneoplastic lesions (7-10). 
I3C is a relatively unstable compound, especially under acid conditions. 
Following dietary administration to rats (and exposure to the acid environment of the 
stomach) I3C undergoes a series of condensation reactions resulting in the production 
of various dimers, linear and cyclic trimers and tetramers (Fig. 4.1), as well as some 
high molecular weight oligomers (11). A number of these condensation products are 
Ah receptor agonists, providing an explanation for the relative potency of orally admin-
istered I3C in the induction of CYP1A1 and 1A2 (12, 13).  I3C induction of CYPs 
also results in altered metabolism of steroid hormones, as in the CYP1A2-dependent 
upregulation of the 2-hydroxylation of estrogens (13), and provides a rationale for the 
utilization of I3C in the chemoprevention of estrogen-dependent tumors (4-6). 
In addition to the well-studied CYP monooxygenase system, mammals possess 
a second major monooxygenase, the flavin-containing monooxygenase (FMO). FMO 61 
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Fig. 4.1. Metabolites of 13C produced in the acid environment of the stomach. 
Under acid conditions, more than 20 metabolites of I3C can be separated by high 
performance liquid chromatography. These include 13C (parent compound); 133', 
(linear dimer); ICZ, indolo-[3,2-]carbazole; LT1, 2,3-bis[3-indolylmethyl]indole 
(a linear trimer); CT, 5,6,11,12,17,18-hexahydrocyclonona[1,2-b:4,5b':7,8bltriindole 
(cyclic trimer); HI-IM, 1-( 3- hydroxymethyl )- indolyl- 3- indolylmethane; and two as yet-
unnamed tetramers, one linear (LTET) and one cyclic (CTET). 
was originally characterized as a distinct monooxygenase in 1972 (14), and has since 
been shown to exhibit activity toward a wide variety of nitrogen-, sulfur-, phosphorus-, 
and selenium-containing xenobiotics (15, 16). Although FMOs and CYPs often display 62 
activity toward many of the same substrates, the resulting metabolites are usually 
distinct, and generally, FMOs tend to produce fewer bioactivated metabolites than 
CYPs (17). 
At the present time the FMO gene family is comprised of five members 
(FMO1 -5). Orthologous isoforms exhibit approximately 80-90% amino acid 
sequence identity, whereas comparisons across gene families show roughly 
50-58% sequence identity (18). FMO1 is the major hepatic form in most adult 
animals, with the exception of primates (19) and female mice (20), where FMO3 
predominates. Unlike the CYP enzymes, FMOs are not induced by exposure to 
xenobiotics. They are regulated both developmentally and by hormone admini-
stration (21). There have been few reports on dietary modulation of FMO (22). 
In this study we report that dietary 13C dramatically inhibits the expression 
of FMO1 in both the liver and intestine of male Fischer 344 rats. Concomitant with 
this inhibition is a marked induction of CYPs, especially CYP1A1 .  The radical 
change in the relative levels of these monooxygenase enzymes should have a 
profound effect on the metabolism and disposition of a wide array of xenobiotics, 
including numerous therapeutic agents. In addition, the advocacy of I3C for 
chemoprevention in humans lends significance to these findings and highlights the 
necessity of determining whether similar phenomena occur in humans. 63 
MATERIALS AND METHODS 
Chemicals and Diet 
I3C was purchased from Aldrich Chemical Co. (Milwaukee, WI) and incorp-
orated into powdered semi-synthetic AIN-76A diet prepared without preservatives. 
The diet was prepared just prior to initiation of the experiment and stored frozen until 
the day before feeding. Thiourea (TU) was also purchased from Aldrich. NADP+, 
glucose-6-phosphate (G6P), glucose-6-phosphate dehydrogenase (G6PDH), catalase, 
acetylthiocholine hydrochloride, and DTNB [5,5'-dithiobis(2-nitrobenzoate)], were 
purchased from Sigma Chemical Co. (St. Louis, MO). All other reagents were ob-
tained at the highest grade possible from various commercial sources. Thiocholine 
(TC) hydrochloride was prepared by methanolysis of acetylthiocholine hydrochloride 
(23). 
Animals 
Four-week old male Fischer 344 rats were purchased from Simonsens (Gilroy, 
CA) and acclimated to AIN-76A diet for a period of 7 days. In the dose-response study, 
rats (four animals per group) were then switched to AIN-76A diet containing 0, 500, 
1000, 1500, 2000, or 2500 ppm (0-0.25%) I3C, and fed ad libitum for 7 additional days. 
In the time-course study, rats (four per group) were fed 2000 ppm (0.20%) I3C ad 
libitum for 0, 1, 2, 7, 14, or 28 days. In each experiment diet intake was monitored 
daily. At the conclusion of each experiment the rats were killed by CO2 asphyxiation, 
liver and intestine were removed, frozen in liquid N2, and stored at -80°C until analysis. 64 
Microsome Preparation and FMO Activity Assay 
Liver and intestinal microsomes were prepared by ultracentrifugation (24). 
Protein was quantified by the method of Lowry et al. (25). FMO activity in micro-
somal tissues was assayed at 37°C by following the TU-dependent oxidation of TC, 
a modification of the method of Guo and Ziegler (23). Initial reaction conditions were 
as follows: 0.1 M potassium phosphate (pH 7.5), 0.4 mM EDTA, 0.25 mM NADP+, 
2.5 mM G6P, 10011M TC, 100 units catalase, and 2 mM benzylimidazole. G6PDH 
was added in sufficient amount to reduce 1 p,mol NADP±/minml, to make a total 
final volume of 2.5 ml. 
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
Immunoblotting 
Microsomal proteins were resolved by SDS-PAGE (26) and electrophoretically 
transferred to nitrocellulose membranes (27). The membranes were incubated with 
rabbit antibody raised against either hog liver FMO1 (a generous gift from Dr. Daniel 
Ziegler, University of Texas at Austin) or CYP1A1 (purchased from Human Biologics, 
Phoenix, AZ). The blots were then probed with a goat anti-rabbit secondary antibody 
conjugated to horseradish peroxidase (Biorad, Richmond, CA) and then visualized 
using a chemiluminescence kit obtained from Amersham Corp. (Arlington Heights, IL). 
Quantitation was performed by densitometry utilizing an HP ScanJet IIcx flatbed 
scanner employing NIH Image version 1.54 software (public domain, Wayne Rasband, 
NIH, available from the Internet). 65 
Statistical Analysis 
Stastistical comparison among the various groups was performed by one-way 
analysis of variance, and differences between control and treated group means were 
compared using least significant difference. All data points are the mean ± SEM for 
four rats per group. The criteria for significance was p < 0.05. 67 
protein levels (Fig. 4.3A) in both liver and intestine. No evidence of toxicity was 
observed with respect to liver weight, body weight gain, food consumption, or gross 
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Figure 4.3.  Dose-response of FMO1 vs. 7-day dietary supplementation with 
0-0.25% (w/w) 13C. Data shown were obtained following densitometry of 
immunoblots proved with antibody to FM01 (black bars) or CYP1A1 (gray bars). 
A representative FM01 blot is shown in the upper right corner. (A) Liver micro-
somes. (B) Intestinal microsomes. (*Denotes values significantly different from 
control.) 68 
examination at necropsy (data not shown). At the highest dose administered (2500 
ppm), liver FMO1 activity was reduced 5-fold (Fig. 4.2A) and FMO1 protein was 
reduced 8-fold (Fig. 4.3A). Intestinal FMO1 activity was reduced 4-fold (Fig. 4.2B) 
at the 2500 I3C dose with almost total ablation of FMO1 protein (Fig. 4.3B). In 
contrast, administration of dietary I3C markedly induced CYP1A1 protein in both 
liver and intestine in a dose-dependent fashion (Fig. 4.3). No CYP1A1 was detected 
in liver or intestinal microsomes from control rats, but cyplAl was induced 30-fold 
in liver and 5-fold in intestine, compared to the lowest dose (500 ppm) administered 
(Fig. 4.3). 
Administration of dietary I3C at a dose of 2000 ppm produced a time-dependent 
reduction in both liver and intestinal FMO1 protein (Fig. 4.4). Time-course experi-
ments revealed that the loss of liver FMO1 protein was apparent as early as day 1 after 
initiation of the I3C diet, and seemed to maximize between days 7 and 14 (Fig. 4.4A). 
In contrast, significant inhibition of intestinal FMO1 protein expression was not evident 
until day 7 of 13C feeding, and continued to decline throughout the 28 days of the study 
(Fig. 4.4B). 69 
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Figure 4.4. Time-course of FMO1 vs. 0-28 days dietary feeding with 0.20 percent 
(w/w) 13C. Data shown obtained following densitometry of immunoblots probed with 
antibody to FMO1 (black bars) or CYPIA1 (gray bars). A representative FMO1 blot 
is shown in the upper right corner. (A) Liver microsomes, (B) Intestinal microsomes. 
(*Denotes values significantly different from control). 70 
DISCUSSION 
FMOs have long been distinguished from CYPs by the lack of modulation of the 
former by exogenous xenobiotics. A notable exception was reported by Kaderlik et al. 
(22) in which rats switched from a commercial chow diet to a chemically defined diet 
exhibited a marked reduction in liver FMO. These results suggested the existence of 
plant-derived constituents capable of FMO induction. In the present study, I3C, a major 
plant constituent of cruciferous vegetables, markedly inhibited FMO1 expression in the 
liver and intestine of rats in both a dose- and time-dependent manner. Conicident with 
the loss of FMO is the frank induction of CYP1A1 levels, a phenomenon previously 
reported by us and other laboratories (12, 13, 28-30). This induction of CYP1A1 and 
other drug-metabolizing enzymes negates the possibility that FMO levels are declining 
due to toxic insult. However, the FMO1 repression measured in this study does not 
appear to be directly linked to CYP1A1 induction per se, as administration of 
13-naphthoflavone to these same animals had no measureable effect on FMO1 
expression (data not shown). 
The net result of dietary I3C administration to these Fischer 344 male rats is a 
remarkable shift from one monooxygenase to another. We hypothesize that this shift 
will produce a dramatic alteration in the metabolism, disposition, and toxicity of a 
number of xenobiotics. Preliminary studies in collaboration with Dr. David Kupfer 
indicate that liver microsomes incubated in vitro with tamoxifen produce less N-oxide, 
greater desmethyltamoxifen and greater covalent binding to microsomal proteins 71 
compared to controls. These findings are consistent with the observed alterations in 
FMO and CYP. 
One caveat to the hypothesis of altered metabolism is the potential for I3C 
condensation products to inhibit either system in vivo. We have previously demon-
strated that the dimer of I3C, 3,3'-diindolylmethane is a potent inhibitor of rat and 
human CYPs (including CYP1A1 and 1A2) with a Ki in the low micromolar range 
(31). Administration of 2000 ppm I3C in the diet to male Fischer 344 rats for 7 days 
results in 1154 [tM 13C equivalents in the liver (11). Of the 24 distinct HPLC peaks 
resolved from liver extracts after oral gavage with 3H-I3C, 3,3'-diindolylmethane is a 
major product, and is present at levels near or exceeding the in vitro K, for CYP1A1. 
Preliminary evidence also suggests the possibility that I3C condensation products can 
inhibit FMO activity in vitro, and is presently under further investigation. 
In conclusion, the result of the redistribution of drug-metabolizing potential in 
animals administered dietary I3C, via induction/repression and inhibition of enzymatic 
activities in vivo, with respect to the disposition of FMO and CYP substrates, awaits 
further study. The promotion of I3C as a chemopreventative agent necessitates the 
investigations into the potential for similar response in humans. 72 
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Chapter 5 
TRANSPLACENTAL EXPOSURE TO INDOLE-3-CARBINOL INDUCES SEX-
SPECIFIC EXPRESSION OF CYP1A1 AND CYP1B1 IN THE LIVER OF  
FISCHER 344 NEONATAL RATS.  
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ABSTRACT  
Previous studies have demonstrated that indole-3-carbinol (I3C), a naturally-
occurring component of broccoli, cabbage, and other members of the family Cruciferae, 
is a potent tumor modulator in several animal models. Dietary administration of I3C to 
Fischer 344 rats has been shown to drastically alter the overall hepatic profile of drug 
metabolizing enzymes, by significantly inducing many Phase I and Phase II enzymes, 
while at the same time inhibiting the expression and activity of others. I3C has 
demonstrated significant chemoprevention against the development of both spontaneous 
and chemically-induced cancers in many animal models, and is at this time undergoing 
evaluation as a chemopreventative agent in human clinical trials. However, other 
researchers have shown I3C, a potent Ah receptor agonist, to be an effective tumor 
promoter in several experimental models. This study examines the disposition of I3C in 
the pregnant rat model, specifically to determine whether I3C can traverse the maternal 
placenta, and what effects, if any, are elicited in the neonate. We now report that dietary 
I3C treatment of pregnant female rats results in appearance of I3C acid condensation 
products in both maternal and neonatal livers. We also report a sex-specific induction 
of CYP1A1 and CYP1B1 protein in new-born livers from I3C-fed dams. CYP1A1 
protein was significantly induced in male neonatal liver, but to a much lesser extent in 
females. Conversely, hepatic CYP1B1 protein was induced to high levels in female 
neonates, but no CYP1B1 protein was detected in their male litter mates. I3C-fed 
maternal liver showed extremely high CYP1A1 protein induction, however no CYP1B1 
protein was detected. No CYP1A1 or CYP1B1 protein was detected in the livers of 
pregnant controls, or their offspring. Our results demonstrate that dietary I3C acid 
condensation products can cross the maternal placenta, and differentially induce 
neonatal hepatic CYP1A1 and CYP1B1 in a sex-specific manner. The results highlight 
I3C's potential to effect profound changes in the overall metabolic profile of the 78 
exposed neonate, and indicate the possible involvement of sex-specific modulators in 
Ah receptor-mediated responses. 
INTRODUCTION 
Indole-3-carbinol (I3C), a naturally-occuring plant alkaloid present in significant 
concentrations in brussel sprouts and other cruciferous vegetables (1), when admin-
istered dietarily, induces a host of phase I enzymes in various species and tissues, 
including CYP1A1/2, CYP2B1/2, and CYP3A1/2 (2-5). The Phase II enzymes UDP-
glucuronosyl transferase (3, 6), NAD(P)H:quinone oxidoreductase (3, 6, 7) and gluta-
thione S-transferase (3, 6, 8, 9) are also induced by dietary I3C. Modulation of these 
xenobiotic-metabolizing enzymes is associated with both decreased tumor incidence, 
and protection against formation of preneoplastic foci in several animal models (10-12). 
Studies have shown that I3C alters the metabolism of steroid hormones in vivo, such as 
the upregulation of the CYP1A2-dependent 2-hydroxylation of estrogens (12). For 
these reasons, I3C is currently being evaluated in human clinical trials, particularly for 
protection against breast, endometrial and other estrogen-related carcinomas 
Other mechanisms of chemoprevention by I3C, not associated with induction of 
detoxication enzymes, have also been observed. Several researchers have reported I3C-
mediated electron scavenging, and intervention in free radical hepatotoxocitiy and lipid 
peroxidation (13, 14) Whether I3C reaches high enough concentrations in vivo to 
perform as an effective antioxidant is unclear. 79 
Chemoprevention is not the only outcome observed with dietary I3C admini-
stration. Several studies indicate I3C can act as a promoter of carcinogenesis, especially 
when administated after a carcinogen (15). Recently, our laboratory reported dietary 
administration of 13C dramatically down-regulated both the expression and activity of 
flavin-containing monooxygenase (FMO), form 1 (16). This down-regulation is assoc-
iated with the concomitant induction of the previously-mentioned CYP1A1, with the 
predicted result of dramatically altered xenobiotic metabolism. 
The parent compound I3C is probably not directly responsible for any of the 
above-mentioned effects. Indole-3-carbinol is a light-sensitive, unstable compound, 
especially under acid conditions. On exposure to the acid environment of the stomach, 
I3C undergoes hydrolysis, yielding a variety of dimers, linear and cyclic trimers (Fig. 
5.1), as well as a host of other, as yet unidentified high molecular weight oligomers 
(17). A number of I3C's acid condensation products (notably diindolylmethane [133] 
and indolocarbazole [ICZ]) have been shown to be potent Ah receptor agonists (4, 5), 
which provides a partial explanation for the relative potency I3C exhibits in the 
induction of CYP1A1 and CYP1A2. 
As I3C is both a naturally-occuring dietary component, and currently being 
evaluated as a chemopreventative, we examined in this study the disposition of I3C in 
the pregnant rat model, specifically to determine whether I3C can traverse the maternal 
placenta, and what effects, if any, are elicited in the neonate. 
We now report that dietary I3C treatment of pregnant female rats results in 
appearance of I3C acid condensation products in both maternal and neonatal livers. 
In maternal liver, a host of I3C oligomers was identified by HPLC analysis. In neo-
natal liver only a single I3C oligomer was detected. This peak was identified as LT1 
(a linear trimer) by HPLC analysis. 80 
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Figure 5.1. A few of the acid-condensation products of indole-3-carbinol.  
These structures have previously been identified in the liver extracts of rats fed I3C  
(16). The compounds are identified as: I3C, indole-3-carbinol (parent compound);  
1CZ, 3,2-b-indolocarbazole; LT, [2- (indol -3- ylmethyl )- indol- 3- yl]- indol -3 -yl- methane;  
CT, 5,6,11,12,17,18-hex-hydrocyclononal[1,2-b:4,5b':7,8-13]:triindole, and 133',  
3,3'-diindolylmethane.  
In addition, we observed a sex-specific pattern of induction of two major Ah-
receptor mediated enzymes, CYP1A1 and CYP1B1. Induction of CYP1A1 protein 
was easily detected in the livers of male neonatal rats from I3C-fed dams, while their 
female litter mates elicited barely-detectable levels. Conversely, female neonates from 
I3C-fed dams showed selective induction of high levels of hepatic CYP1B1, while no 
CYP1B1 was detected in the livers of their male litter mates. No CYP1A1 or CYP1B1 
protein was detected in the livers of controls dams, or in the livers of male or female 
pups from control dams. 81 
This study demonstrates that some I3C oligomers have the ability to traverse the 
maternal placenta in the rat, and can alter the overall metabolic profile of the neonate. 
The observed differential induction of xenobiotic metabolizing enzymes in the exposed 
neonates could have profound effects on the metabolism of endogenous substrates, as 
well as the potential for selective activation of xenobiotics. These results indicate the 
possible involvement of sex-specific modulators in the early developmental expression 
of Ah receptor-mediated responses, and underscore the need for caution in the use of 
I3C in ongoing chemoprevention trials. 82. 
MATERIALS AND METHODS 
Chemicals 
Indole-3-carbinol was obtained from Aldrich (Milwaukee, WI). 13C acid 
condensation products (133', ICZ, CT and LT) were generated by the method of 
Bj eldanes et al. (4). 
Animals 
Timed-pregnant Fischer 344 rats were purchased from Simonsens (Gilroy, CA) 
at day 10 of gestation. Animals were randomly divided into two groups and fed either 
AIN93G powdered semi-synthetic control diet, or control diet containing 2000 ppm 
indole-3-carbinol for the next 11 days until parturition. Both water and diet were avail-
able ad libitum throughout the study. Animals nearing parturition were monitored 
constantly and at birth, neonates were immediately separated from the mother before 
they could nurse, to avoid any possible lactational exposure. Immediately after par-
turition all pups were separated by sex (as determined by measurement of ano-genital 
distance). Animals were then killed by CO2 asphyxiation (pups were sacrificed by CO2 
asphyxiation plus decapitation). and the livers were removed. A portion of the maternal 
liver was removed for extraction of I3C acid condensation products. A number of fetal 
livers were also randomly selected and set aside for extraction of I3C acid condensation 
products. All liver samples were quick-frozen in liquid nitrogen, and stored at -80°C 
until analysis. (Note: one rat pup was excluded from the study. The pup, from control 
dam #2, was delivered normally, but was incompletely formed, born dead, and of 
indeterminate sex.). 
Microsome Preparation 
Maternal and neonatal livers were homogenized by hand in glass homogenizers 
kept on ice, using four volumes of homogenization buffer (0.1 M potassium phosphate 83 
[pH 7.25], containing 0.15 M potassium chloride, 1.0 mM EDTA, 0.1 mM 
phenylmethylsulfonylfluoride, 1.0 mM dithiothreitol, and 20 mM butylated 
hydroxytoluene (BHT). Liver microsomes were then prepared by ultracentrifugation 
(18). Protein levels were determined by the method of Lowry et al. (19). 
Electrophoresis and Immunoblotting 
Microsomal proteins were resolved by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) (20), then electrophoretically transferred to nitro-
cellulose membranes (21). The membranes were incubated with rabbit antibody raised 
against either rat CYP1A1 (purchased from Human Biologics, Phoenix, AZ) or mouse 
CYP1B1 (a generous gift from Dr. Colin Jefcoate, University of Wisconsin). The blots 
were probed with a goat anti-rabbit secondary anitbody conjugated to horseradish 
peroxidase (Biorad, Richmond, CA), then visualized by a chemiluminescence detection 
kit (Amersham Corp, Arlington Heights, IL). Quantitation of bands was perfomed by 
densitometry of auto-radiographs utilizing a ScanJet hex flatbed scanner (Hewlett-
Packard Co., Palo Alto, CA) employing NIH Image version 1.54 software (public 
domain, Wayne Rasband, NIH, available from the Internet). 
Tissue Extraction 
Maternal and neonatal livers were initially homogenized as described above. 
Homogenates were then extracted three times each with three volumes of ice cold ethyl 
acetate (containing 0.001% BHT). The extract was kept on ice, shielded from light, 
and evaporated to near dryness under a gentle stream of nitrogen. The final residue was 
stored at -80°C, then redisolved in tetrahydrofuran (THF) just prior to HPLC analysis. 84 
HPLC Analysis 
A standard I3C acid reaction mixture was prepared as previously described (4) 
and used to generate a sample chromatogram to establish retention time of I3C 
oligomers dissolved in THF. Oligomers were separated by HPLC at 30°C with a 
Beckman Ultrasphere C-18 analytical column, 4.6 mm x 25 cm, 5 gm pore size. Peaks 
were detected at 280 nm by a Shimadzu SPD-6AV UV/VIS detector (Kyoto, Japan) 
and recorded by a Shimadzu Chromatopac integrator (Kyoto, Japan). Flow rate was 
held constant at 1 ml/min.throughout the analysis.  Initial conditions were: 20% aceto-
nitrile (solvent A), 80% water (solvent B). These conditions were held constant for 0.5 
min., then a linear gradient to 85% solvent A was run over the next 29.5 min., and held 
for 5 minutes. Solvent A was then increased to 100% linearly over the next 5 minutes, 
and held constant at 100% Solvent A for an additional 5 min. At t = 45 minutes the 
mobile phase was then gradually returned to the starting composition over the next 10 
minutes. 88 
extracts of both an I3C-treated dam (Fig. 5.5B), and a representative chromatogram 
from an I3C-exposed pup (Fig. 5.5C). Many I3C derivatives are readily identified in 
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Figure 5.5. HPLC chromatograms of (A) typical in vitro-generated  
reaction mixture, (B) ethyl acetate extract liver taken from BC-fed dam, and (C)  
ethyl acetate extract of neonatal liver from BC-fed dam, monitored at 280 nm.  
Some of the I3C derivates identified by previously generated standards are I3C (parent  
compound); 133', 3,3'-diindolylmethane; CT, cylic trimer; and LT, a linear trimer.  89 
the ethyl acetate extract from the adult rat. Prominent peaks are tentatively identified 
based on co-eluation with previously-isolated standards. 
DISCUSSION  
A diet rich in cruciferous vegetables has been assosciated with a lower incidence 
of cancer (1), and this chemoprotection is thought to be partially mediated by I3C, and 
its ability to induce Phase I and Phase II enzymes (2-9). Although the mechanisms of 
induction of these enzymes is not completely understood, certain I3C derivatives are 
known to bind with relatively high affinity to the Ah receptor (4, 5), with subsequent 
translocation to the nucleus. There they react with specific xenobiotic response 
elements (XREs) in the upstream region of CYP genes, inducing their expression 
(22, 23). 
Previous researchers have isolated I3C derivatives from the livers of I3C-fed 
animals (17). We now report the detection of at least one I3C derivative in the neonatal 
rat liver from I3C-fed mothers. Since animals were removed from the mother at birth, 
and were not allowed to nurse, it is assumed that I3C derivatives are capable of 
traversing the maternal placenta. Further, we have shown that this transplacental 
exposure results in a sex-specific induction of CYP enzymes. CYP1A1 was induced to 
significant levels in males neonates only, wherease CYP1B1 was selectively induced in 
female litter mates. 90 
The basis for the differential inducibility of these CYP1A1 and CYP1B1 
Enzymes in rat neonates is unknown, but apparently cannot be accounted for strictly 
by differences in either Ah receptor or ARNT protein expression, since both are known 
to mediate CYP1A1 and CYP1B1 responses (24-26). Our results, and others suggest 
some other sex-dependent modulator(s) may be invovled. Hakkola et al. recently 
reported expression CYP1B1 in human placenta to be regulated independently from 
CYP1A1 (27), although a sex-dependence was not investigated. Horseman et al. have 
shown that CYPs display a sex-dependence in consitutive as well as inducible patterns 
of expression, mediated by sex-specific differences in secretion of growth hormone 
(28). Walker et al. noted a sex-dependent expression of CYP1B1 in the kidneys and 
livers of TCDD-treated adult Sprague-Dawley rats, however no sex-dependent 
difference in CYP1A1 expression was noted (29). And TCDD has been shown to be 
more hepatocarcinogenic in female rats than in males (30). Estrogen has been 
implicated as an important mediator of these sex-specific phenomena (31). Evidence 
suggests that CYP1A1 and CYP1B1 metabolize estrogen to 2-hydroxyestradiol and 
4-hydroxyestradiol respectively, which can then undergo free-radical generation by 
redox cycling (32, 33). The resultant increase in oxidative stress from production of 
these catechol estrogens may contribute to the observed sex-dependent carcinogenicity 
of TCDD in exposed female rats. 
Further studies are required to determine the possible role of sex-specific 
modulators of CYP1A1 and CYP1B1 expression. In addition, examination of the 
developmental patterns of induction of these enzymes in fetal tissues should be done to 
determine the tissue-specific potential for metabolic activation in the developing fetus. 91 
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Chapter 6 
IN VITRO INHIBITION OF FMO1 AND FMO2 ACTIVITY BY  
THE ACID-CONDENSATION PRODUCTS OF INDOLE-3-CARBINOL  
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ABSTRACT 
Indole-3-carbinol (I3C), a naturally-occurring alkaloid in broccoli, brussel 
sprouts and other cruciferous vegetables, is a potent tumor modulator in vivo, and is 
currently being investigated in clinical trials for chemoprevention of breast cancer, 
endometrial cancer, and other estrogen-related cancers. However, I3C can also elicit 
various promotional effects. I3C is quite unstable, especially under acid conditions, 
and can undergo condensation reactions, leading to production of various dimers, 
trimers and other higher-order oligomers. Some of these condensation products have 
been shown to be Ah receptor agonists, as well as potent inducers of many cytochrome 
P450s (CYPs). Coincident with the ability of 13C to upregulated CYPs, we have 
previously shown that dietary administration of I3C to Fischer 344 rats leads to down-
regulation of FMO1 expression and activity in liver and other tissues. In this study we 
attempted to determine if I3C could inhibit the in vitro activity of FMO1 and FMO2, 
and if so, which 13C derivative(s) was responsible. A crude reaction mixture was 
prepared by acid hydrolysis of 13C, followed by HPLC separation, collection and 
concentration of the following 13C derivatives: I3C, parent compound; 133', 3,3'-
diindolylmethane; 3,2-b-indolocarbazole; HI-IM, 1-(3-hydroxymethypindoly1-3-
indolylmethane; LT, [2-(indo1-3-ylmethyl)-indol-3-yl]indoly1-3-ylmethane; and CT, 
5,6,1 1,12,17,1 8-hex-hydrocyclo-nona[1,2-b:4,5-b':7,8-b]:triindole. These derivatives 
were then tested for their ability to inhibit the S-oxidation of methimazole (N-methy1-
2-mercaptoimidazole). Results showed that FMO1 activity was inhibited by ICZ, 
133', and HI-IM, with a K, values of 31.0 [molar, 42.4 [molar and 76.4 !molar 
respectively. FMO2 activity was also inhibited, but to a much lesser extent, by the 97 
I3C derivatives 133' (K, = 124.8 !molar) and ICZ (K, = 181.5 limolar). The inhibition 
patterns of both FMO1 and FMO2 indicate a competetive type of inhibition. We have 
shown that I3C derivatives can inhibit FMOs in vitro. Whether these derivatives act 
alone, or in combination, or are present in vivo in concentrations approaching their in 
vitro inhibition levels has yet to be determined.  Also, given that over 40 peaks are 
identifiable on an HPLC chromatogram, further testing of other-as yet-unidentified 
derivatives will be required. 98 
INTRODUCTION 
Flavin monooxygenases (FMOs) catalyze the NADPH-dependent oxidation 
of a variety of soft nucleophiles containing nitrogen, sulfur, phosphorus and selenium 
atoms (1,2). This multi-gene family of enzymes, located in the endoplasmic 
reticulum, displays a broad substrate specificity, and plays an important role in both 
the activation and detoxification of many drugs, pesticides and other xenobiotics (3,4). 
Although FMOs are found in nearly all mammalian tissues, their endogenous function 
is, as yet, unknown. FMOs are both species- and tissue-specific, developmentally 
regulated, and modulated by sex steroids and glucocorticoids (5-7). However, unlike 
the CYP enzymes, which are inducible by a wide range of xenobiotics, FMOs are 
quite refractory to induction by diet or xenobiotics, and few, if any, exogenous 
inhibitors have previously been identified. 
Indole-3-carbinol (I3C) is a naturally-occurring compound found in cauli-
flower, broccoli, cabbage, and other members of the family Cruciferae. When 
exposed to sunlight, or the acid environment of the stomach, I3C undergoes 
condensation reactions to produce a variety of dimers, trimers and other high-order 
derivatives (8-9). When incorporated into the diet, I3C and some of its acid-derived 
metabolites bind to the aryl hydrocarbon (Ah) receptor, and strongly induce many 
Phase I and Phase II enzymes, both in vivo and in vitro (8-1 1). It is this ability to alter 
enzyme expression that is believed responsible for the observed reduction in Ah-
induced neoplasia in experimental animals (9-13). 13C can act as both an inhibitor and 
a promoter of aflatoxin-induced carcinogenesis, depending on the time of admini-
stration (14-15). 13C has also been shown to alter the levels of competing pathways of 100 
An acid reaction mixture was generated by the method of Bjeldanes et al. (8), 
and 13C derivative was isolated and purified via HPLC. Each of the major products 
(I3C parent compound, HI-IM, 133', ICZ and LT) were applied to a simple, but highly 
sensitive spectrophotometric assay for FMO1 and FMO2 activity, the S-oxidation of 
methimazole, which is an excellent substrate for most FMO isoforms. Results showed 
FMO1 was inhibited by ICZ, 133' and HI-IM with K, values of 31.0 i.tmolar, 42.4 
pimolar, and 76.4 limolar respectively. FMO2 activity was inhibited to a much lesser 
extent by ICZ (K; = 128.4 !molar) and 133' (K, = 181.5 !molar). 
Because over 40 peaks are identified on a typical HPLC chromatogram of I3C 
acid condensation products, further studies will be required to isolate and identify 
these other, potentially active compounds. 101 
MATERIALS AND METHODS 
Chemicals 
Indole-3-carbinol (I3C) was purchased from Aldrich Chemical Co. 
(Milwaukee, WI). Methimazole (N- methyl -2- mercaptoimadazole), potassium 
phosphate, dithiothreitol (DTT), NADPH, glucose-6-phosphate, glucose-6-phosphate 
dehydrogenase, tricine, EDTA, benzylimidazole, and DTNB (5,5'-dithiobis[2-nitro-
benzoate]) were purchased from Sigma Chemical CO. (St. Louis, MO). Purified hog 
liver FMO1 was a generous gift from Dr. Daniel Ziegler (University of Texas at 
Austin). FMO2 was purified from pregnant female New Zealand rabbit lung as 
described previously by Williams, et al. (18). 
HPLC Separation of I3C Derivatives 
An I3C acid-catalytzed reaction mixture was generated by the method of 
Bjeldanes et al. (8), and used to generate a reference chromatogram of retention 
times for I3C oligomers dissolved in THF. The individual oligomers (133', HI-IM, 
ICZ and LT1) were identified with references standard oligomers previously 
produced. HPLC separation was performed at 30°C utilizing a Shimadzu SPD-6AV 
spectrophotometer, monitored with a UVNIS detector (Kyoto, Japan) at 280 mn. 
The HPLC was outfitted with an Ultrashpere C-18 column, 4.6 mm x 25 cm, 51AM 
pore size. Gradient conditions were as follows: Initial: Solvent A = acetonitrile, 
20%; Solvent B = water, 80%. Initial conditions were held constant for 0.5 min., then 
switched to a linear gradient over 29.5 minutes to 85% Solvent A, where it was then 
held for 5 minutes. Solvent A was again increased to 100% linearly over the 102 
next 5 minutes, and held constant for an additional 5 minutes. The mobile phase 
was then gradually returned to the starting composition of the next 10 minutes. 
Flow was held constant at 1 in/min. throughout the analysis. An injection loop of 
50 ill was used. 
Methimazole Assay 
The UV/VIS spectrophotometric assay of the S-oxidation of methimazole was 
conducted as per the method of Dixit et al (19). 103 
RESULTS 
FMO1 and FMO2 Inhibition Assay 
Of the five compounds tested (parent I3C, I33', ICZ, HI-IM and LT), three of 
these were shown to be effective inhibitors of the in vitro FMO1- mediated S-oxidation 
of methimazole (Figure 6.2). 
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Figure 6.2. Inhibition of pig liver FMO1 by indole-3-carbinol and its derivatives. 
This assay follows the S-oxidation of methimazole by the flavin-containing mono-
oxygenase, followed by UVNIS spectrometry at 412 nm. Results were plotted as 
the change in absorbance/min/mg protein versus increasing total concentrations of 
13C oligomer in assay. ICZ gave the strongest FMO1 inhibition, followed by I33' 
and HI-IM. Neither Parent I3C or LT, the linear trimer, were inhibitory in this assay. 104 
A double-reciprocal (Lineweaver-Burk) plot of the results for FMO1 (shown 
in the previous figure) determined the K, of ICZ to be 31.0 !molar (Fig. 6.3).  133' 
was also an effective inhibitor of FMO1, with a Ki calculated to be 42.4 !molar. The 
HI -IM dimer inhibited FMO1 to a lesser extent, with a K, = 76.4 !molar. 
O  ICZ 
k.  HI-1M 
Figure 6.3. Double-reciprocal plot of FMO1 inhibition data. IC, values (molar): 
ICZ = 31.2, 133' = 42.4, HI-IM = 76.1. 
The S-oxidation of methimazole was again determined, this time with purified 
rabbit lung FMO2 isoform (Fig. 6.4). ICZ and 133' were found to inhibit FMO2 
activity in the methimazole assay system. The parent compound I3C and LT were 
found to be ineffective in inhibiting FMO2 activity, consistent with the FMO1 assay 
results. However the dimer HI -IM which was shown to be a weak inhibitor of FMO1, 
had no measurable effect on FMO2 activity. 106 
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Figure 6.5. Double-reciprocal plot of FMO2 inhibition data. Ki values (molar): 
133' = 124.8, ICZ = 181.5. 
FMO1 in vitro, with a K, of 31.0 [molar, FMO2 appeared to be 6 times less sensitive 
to the effects of ICZ, and was only weakly inhibited by ICZ (K, = 181.5 ',molar). 133' 
was also an effective inhibitor of FMO1 activity as examined in this assay, with only a 
slightly higher K, value (42.4 'molar) than that of ICZ. 
Overall, FMO1 seemed to be much more senstitive to the inhibitory effects of 
13C derivatives than FMO2, which was quite refractory to inhibition, and required 
relatively high levels of 133' and ICZ to influence activity. The parent compound, I3C 
and LT, the linear trimer, were not found to inhibit either FMO1 or FMO2. 107 
DISCUSSION  
Previous experiments determined I3C to be an in vivo inhibitor of FMO1 
expression and activity in the Fischer 344 male rat (17). It was hypothesized at 
that time that the mechanism of this down-regulation was linked to changes in the 
hormonal profile of the rat, since oral I3C administration has been shown to alter 
estrogen metabolism in vivo (16), and steroid hormones are known inducers of FMO 
expression (3, 6, 18). With the exception of steroid induction, FMOs have long been 
thought to be refractory to xenobiotic modulation, especially compared to the CYP 
family of monooxygenases, and researchers have speculated that FMOs might be 
"maintained" in an endogenously induced state by native steroid hormone profiles, 
and that unless a drug or other xenobiotic (like I3C) produced marked changes in 
progesterone, testosterone, f3- estradiol or other steroid hormones, FMOs would be 
retained in their normal "induced" state (5). 
This study, however, shows that derivatives of I3C, in addition to demon-
strating in vivo inhibition of FMO1 expression, may be acting as inhibitors of FMO1 
activity itself. In fact, many of the oligomers assayed in this study (133', HI-IM, and 
LT) are found in appreciable amounts in the extracted livers of rats fed I3C (9). ICZ, 
found to be one of the most potent in vitro inhibitors of FMO1 and FMO2 activity in 
this study, is found in only small quantities in both I3C reaction mixture and in liver 
extracts from 13C -fed rats (9). ICZ has been shown to be an effective inducer of some 
P450 enzymes, even at low nanomolar concentrations, and binds with high affinity to 
the Ah receptor (20). The dimer 133', although a low-affinity Ah receptor agonist, is 108 
still able to induce CYP1A1 with relative efficiency (21), and previously has been 
shown to be an in vitro inhibitor of trout, rat and human CYP1A1 (22-24). 
It has yet to be demonstrated at what concentrations these I3C derivatives may 
inhibit FMO1 in vivo, but preliminary studies indicate that there does not appear to be 
a high enough concentration of inhibitory oligomer recovered from the liver of I3C-
fed rats to account for the measured inhbition (9). However, as noted previously, a 
simple acid condensation mixture of I3C yields 30-40 peaks on HPLC analysis. It is 
possible that one of these yet-to-be-identified derivatives is responsible for the bulk 
of inhibition measured, or that a combined action of several derivatives at a site is 
quantitatively important in vivo. 
Results also show a much greater in vitro inhibition of FMO1 than FMO2 
activity with the derivatives we tested. This phemonomen may reflect the more 
restrictive nature inherent in the FMO2 enzyme active site, as compared with that 
of FMO1. It has long been known that FMO1 but not FMO2 was capable of the 
efficient N-oxidation of the relatively bulky short side chains of tertiary amines, like 
imipramine and chlorpromazine (25). Ziegler et al. have demonstrated, using 
substituted thiocarbamides of increasing size, that bulkier substrates are selectively 
excluded from the active site of FMO2 (26). Since the catalytic mechanisms are 
essentially the same for FMO1 and FMO2 (2, 27), researchers concluded that 
FMO2 possesses a long, narrow substrate binding channel, wherease FMO1 has a 
shallower and broader substrate binding domain. It is, therefore, possible that these 109 
I3C metabolites that inhibit FMO1 activity at low micromolar concentrations have a 
more difficult time interacting with the more restricted active site of FMO2. 
At the present time, concentrated extracts of broccoli and other cruciferous 
vegetables are easily obtainable at most health foods stores and vitamin-supply 
outlets. The unrestricted and unsupervised dietary supplementation with these 
over-the-counter preparations could drastically alter "normal" metabolism in 
unsuspecting individuals, and could represent a risk for the "well-intended" user. 
Also, at this time, I3C is undergoing clinical trials for use as a chemopreventative 
agent for estrogen-related cancers. Given that I3C not only induces a host of CYP 
enzymes, but also inhibits FMO protein expression and activity as well, profound 
changes in the overall metabolism of xenobiotics is predicted for these patients. 110 
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SUMMARY  
In this thesis we demonstrate that the flavin-containing monooxygenase 
isoforms FMO1 and FMO2 are regulated both developmentally and by dietary 
exposure in fetal, neonatal and adult tissues. The presence of these enzymes 
in active form in fetal and neonatal lung and liver indicates that, contrary to 
previously held dogma, the fetus is capable of independent metabolism and/or 
activation of xenobiotics, and can be sensitive to chemical exposures through 
transplacental or lactational routes. We also report the expression of FMO isoforms 
is tissue-specific. Since FMO2 protein levels appeared to be induced in fetal lung, 
but FMO1 protein in fetal liver did not, we hypothesize that these two enzymes are 
regulated by independent mechanisms. Further studies on the 5' upstream regulatory 
regions of these enzymes will be required to verify these results. 
We have also demonstrated a naturally-occurring dietary component (indole-
3-carbinol) that down-regulates the expression and activity of FMO1. This is the first 
known illustration of a dietary or other xenobiotic compound down-regulating 
expression of an FMO isoform in vivo. It was postulated that the observed effects of 
I3C on FMO may be due to changes produced in the levels of endogenous hormones 
like estrogen, since I3C has been known to alter in vivo estrogen metabolism (1). 
However, additional studies found I3C to be an in vitro inhibitor of FMO activity as 
well. Since I3C derivatizes in the acid environment of the stomach (2), experiments 
were performed to determined which derivative(s) of I3C could be responsible for the 
observed in vivo inhibition. Results revealed differential inhibition of FMO isoforms 115 
by these oligomers, which strongly supports other evidence that the three-dimensional 
character of FMO1 and FMO2 substrate binding channels is quite different (3-6). 
FMO2, purported to have a more restricted substrate binding pocket, was poorly 
inhibited by 13C derivatives, whereas FMO1 with its larger, shallower substrate 
binding pocket, was inhibited at low micromolar levels by several 13C derivatives. 
Experiments were performed to determine if 13C derivatives could cross the 
maternal placenta and alter expression of xenobiotic metabolizing enzymes in the fetus. 
Results showed that 13C derivatives could be isolated from livers of neonates from 13C-
fed mothers, and dramatic changes were noted in CYP enzyme expression in these 
exposed neonates. This expression was sex-specific, with CYP1A1 induced in exposed 
male neonates, while CYP1B1 was induced in exposed female neonates. These results 
implicate a sex-specific regulatory factor in the Ah-induced expression CYP enzymes. 
Overall, we have demonstrated that xenobiotic metabolizing enzymes are 
present and active in the developing fetus, and can be profoundly influenced by either 
transplacental or lactational xenobiotic exposures. Naturally-occurring compounds are 
also capable of modulating fetal enzyme levels. These factors should be taken into 
consideration when assessing exposure risk scenarios for both the fetus and the neonate. 116 
REFERENCES  
1.	  Brad low, H. L., Michnovicz, J. J., Telang, N. T., and Osborne, M. P. Effects 
of dietary indole-3-carbinol on estradiol metabolism and spontaneous 
mammary tumors in mice. Carcinogenesis 12, 1571-1574 (1991). 
2. Bjeldanes, L. F., Kim, J.-Y., Grose, K. R., Bartholomew, J. C., and Bradfield, 
C. A. Aromatic hydrocarbon responsiveness-receptor agonists generated 
from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetra-
chlorodibenzo-p-dioxin. Proc. Natl. Acad. Sci. U.S.A. 88, 9543-9547 
(1991). 
3. Nagata, T., Williams, D. E., and Ziegler, D. M. Substrate specificities of rabbit 
lung and procine liver flavin-containing monooxygenases: Differences due 
to substrate specificity. Chem. Res. Toxicol. 3, 372-376 (1990). 
4. Rettie, A. E., Bogucki, B. D., Lim, I., and Meier, G. P. Stereoselective sulfoxi-
dation of a series of alkyl p-tolylsulfides by microsomal and purified flavin-
containing monooxygenases. MoL Pharmacol. 37, 643-651 (1990). 
5. Guo, W.-X. A., Poulsen, L. L., and Ziegler, D. M. Use of thiocarbamides as 
selective substrate probes for isoforms of flavin-containing monooxygenases. 
Biochem. Pharm. 44, 2029-2037 (1992). 
6. Ziegler, D. M. Recent studies on the structure and function of multisubstrate 
flavin-containing monooxygenases. Annu. Rev. Pharmacol. Toxicol. 33, 
179-199 (1993). 117 
BIBLIOGRAPHY 
1.	  Agosin, M. and Ankley, G. T. Conversion of N, N-dimethylaniline to N,N-
dimethylaniline-N-oxide by a cytosolic flavin-containing enzyme from 
Trypanosoma cruzi. Drug. Metab. Dispos. 15, 200-203 (1987). 
2.	  Akerboom, T. P. M., Sies, H., and Ziegler, D. M. The oxidation of Ebselen 
metabolites to thiol oxidants catalyzed by liver microsomes and perfused 
rat liver. Arch. Biochem. Biophys. 316, 220-226 (1995). 
3.	  Al-Waiz, M., Mitchell, S. C., Idle, J. R., and Smith, R. L. The metabolism of 
14C-labeled trimethylamine and its N'oxide in man. Xenobiotica 17, 551-
558 (1987). 
4.	  Al-Waiz, M., Ayesh, R., Mitchell, S. C., Idle, J. R., and Smith, R. L. Trimethyl-
aminuria: the detection of carriers using a trimethylamine load test. J. 
Inherited Metab. Dis. 12, 80-85 (1989). 
5.	  Ayesh, R., Mitchell, S. C., Zhang, A., and Smith, R. L. The fish-odor syndrome: 
biochemical, familial and clinical aspects. Br. Med. J. 307, 655-657 (1993). 
6.	  Ballard, P. L. and Ballard, R. A. Glucocorticoid receptors and the role of 
glucocorticoids in fetal lung development. Proc. Natl. Acad. Sci. U.S.A. 
69, 2668-2672 (1972). 
7.	  Beaty, N. S. and Ballou, D. P. The reductive half-reaction of liver microsomal 
FAD-containing monooxygenase. J. Biol. Chem. 256, 4611-4618 (1981a). 
8.	  Beaty, N. S. and Ballou, D. P. The oxidative half-reaction of liver microsomal 
FAD-containing monooxygenase J. Biol. Chem. 256, 4619-4625 (1981b). 
9.	  Bhattacharyya, K. K., Brake, P. B., Eltom, S. E., Otto, S. A. and Jefcoate, C. R. 
Identification of a rat adrenal cytochrome P450 that exhibits sex-dependent 
expression in livers and kidneys of TCDD-treated animals. Carcinogenesis 
16, 1319-1327 (1995). 
10.  Bjeldanes, L. F., Kim, J.-Y., Grose, K. R., Bartholomew, J. C., and Bradfield, 
C. A. Aromatic hydrocarbon responsiveness-receptor agonists generated 
from indole-3-carbinol in vitro and in vivo: comparison with 2,3,7,8-tetra-
chlorodibenzo-p-dioxin. Proc. Natl. Acad. Sci. U.S.A. 88, 9543-9547 (1991). 
11.	  Boone, C. W., Kelloff, G. J., and Malone, W. E. Identification of candidate cancer 
chemopreventative agents and their evaluation in animal models and human 
clinical trials: a review. Cancer Res. 50, 2-9 (1990). 118 
12. Brad low, H. L., Michnovicz, J. J., Telang, N. T., and Osborne, M. P. Effects of 
dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary 
tumors in mice. Carcinogenesis 12, 1571-1574 (1991). 
13. Cashman, J. R., and Olsen, L. D. Stereoselective S-oxygenation of 2-ary1-1,3-
dithiolanes by the flavin-containing and cytochrome P-450 monooxygenases. 
Mol. Pharmacol. 38, 573-578 (1990). 
14.	  Cashman, J. R., Park, S. B., Yang, Z.-C., Wrighton, S. A., Jacob, P., III, and 
Benowitz, N. L. Metabolism of nicotine by human liver microsomes. 
Stereoselective formation of trans-nicotine N'-oxide. Chem. Res. Toxicol. 
5, 639-646 (1992). 
15. Cashman, J. R. Structural and catalytic properties of the mammalian flavin-
containing monooxygenase. Chem. Res. Toxicol. 8, 165-181 (1995). 
16.	  Chen, I., Safe, S., and Bjeldanes, L. Indole-3-carbinol and diindolylmethane 
as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D breast 
cancer cells. Biochem. Pharm. 51, 1069-1076 (1996). 
17.	  Chen, Y. C., Peoples, 0. P., and Walsh, C. T. Acinetobacter cyclohexanone 
monooxygenase: gene cloning and sequence determination. J. Bacteriol. 
170, 781-789 (1988). 
18.	  Chomczynski, P., and Sacchi, N. Single-step method for RNA isolation by acid 
guanidinium-thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 
156-159 (1987). 
19. Damani, L. A., Pool, W. F., Crooks, P. A., Kaderlik, R. K, and Ziegler, D. M. 
Stereoselectivity in the N'-oxidation of nicotine isomers by flavin-containing 
monooxygenase. Mol. Pharmacol. 33, 702-705 (1988). 
20.	  Danger, D. P., Baldwin, W. S., and LeBlanc, G. A. Photoaffinity labeling of 
steroid hormone-binding glutathione S-transferases with [3-H]methyltri-
enolone. Biochem. J. 288, 361-367 (1992). 
21. Damian, G. A. and Guengerich, F. P. Immunochemical comparison and 
quantitation of microsomal flavin-containing monooxygenases in various 
hog, mouse, rat, rabbit, dog and human tissues. Mol. Pharmacol. 22, 
787-794 (1982). 119 
22. Darman, G. A., Guengerich, F. P., and Waxman, D. J. Hormonal regulation  
of rat liver microsomal enzymes. Role of gonadal steroids in programming,  
maintenance, and suppression of A4- steroid 5a-reductase, flavin-containing  
monooxygenase, and sex-specific cytochromes P-450. J. Biol. Chem. 261,  
10728-10735 (1986).  
23. Dashwood, R. H., Fong, A. T., Williams, D. E., Hendricks, J. D., and Bailey, G. S. 
Promotion of aflatoxin B1 carcinogenesis by the natural tumor modulator 
indole-3-carbinol: influence of dose, duration and intermittent exposure on 
indole-3-carbinol promotional potency. Cancer Res. 51, 2362-2365 (1991). 
24. Decker, C. M., Doerge, D. R., and Cashman, J. R. Metabolism of benzimidazo-
line-2-thiones by rat hepatic microsomes and hog liver flavin-containing 
monooxygenase. Chem. Res. Toxicol. 5, 726-733 (1992). 
25.	  Denison, M. S., Fisher, J. M., and Whitlock, J. P., Jr. Protein-DNA interaction 
at recognition sites for the dioxin Ah-receptor complex. J. Biol. Chem. 264, 
16478-16482 (1989). 
26. Deuscher, R. J., Lawton, M. P., Philpot, R. M., and Elfarra, A. Flavin-containing 
monooxygenase (FMO)- dependent metabolism of methionine and evidence 
for FMO3 being the major FMO involved in methionine sulfoxidation in 
rabbit liver and kidney microsomes. J. Biol. Chem. 269, 17525-17530 (1994). 
27. Devereux, T. R. and Fouts, J. R. N-oxidation and demethylation of N,N-di-
methylaniline by rabbit liver and lung microsomes. Effects of age and 
metals. Chem. -Biol. Interact. 8, 91-105 (1974). 
28. Devereux, T. R. and Fouts, J. R. Effects of pregnancy or treatment with certain 
steroids on N,N-dimethylaniline demethylation and N-oxidation by rabbit 
liver and lung microsomes. Drug. Metab. Dispos. 3, 254-258 (1975). 
29. Devereux, T. R., and Fouts, J. R. The effect of Hg2+ on rabbit hepatic and 
pulmonary solubilized, partially purified N,N-dimethylaniline N-oxidases. 
Chem. -Biol. Interact. 18, 277-287 (1977). 
30.	  Devereux, T. R. and Fouts, J. R. Effect of dexamethasone treatment on N,N-
dimethylaniline demethylation and N-oxidation in pulmonary microsomes 
from pregnant and fetal rabbits. Biochem. Pharmacol. 27, 1007-1008 (1978). 
31.	  Dixit, A., and Roche, T. E. Spectrophotometric assay of the flavin-containing 
monooxygenase and changes in its activity in female mouse liver with 
nutritional and diurnal conditions. Arch. Biochem. Biophys. 233, 50-63, 
(1984). 120 
32. Dolphin, C., Shepard, E. A., Povey, S., Palmer, C. N., Ziegler, D. M., Ayesh,  
R., Smith, R. L. and Phillips, I. R. Cloning, primary sequence and chromo-
somal mapping of a human flavin-containing monooxygenase (FMO1).  
J. Biol. Chem. 266, 12379-12385 (1991). 
33.	  Duffel, M. W., Graham, J. M., and Ziegler, D. M. Change in dimethylaniline  
N-oxidase activity of mouse liver and kidney induced by steroid sex  
hormones. Ma Pharmacol. 19, 134-139 (1981).  
34.	  Engler-Blum, G., Meier, M., Frank, J., and Muller, G. A. Reduction of back-
ground problems in nonradioactive northern and southern blot analyses 
enables higher sensitivity than 32P-based hybridizations. Anal. Biochem. 
210, 235-244 (1993). 
35.	  Falls, J. G., Blake, B. L., Cae, Y., Levi, P. E., and Hodgson, E. Gender 
differences in hepatic expression of flavin-containing monooxygenase 
isoforms (FM01, FMO3 and FMO5) in mice. J. Biochem. Toxicol. 10, 
171-177 (1995). 
36.	  Feinberg, A. P., and Vogelstein, B. A technique for radiolabeling DNA 
restriction endonuclease fragments to high specific activity. Anal. Biochem. 
132, 6-13 (1983). 
37. Fong, A. T., Swanson, H. I., Dashwood, R. H., Williams, D. E., Hendricks, 
J. D., and Bailey, G. S. Mechanisms of anti-carcinogenesis by indole-3-
carbinol: studies of enzyme induction, electrophile-scavenging, and 
inhibition of aflatoxin B1 activation. Biochem. Pharmacol. 39, 19-26 
(1990). 
38.	  Gasser, R., Negishi, M., and Philpot, R. M. Primary structures of multiple forms 
of cytochrome P-450 isozyme 2 derived from rabbit pulmonary and hepatic 
cDNAs. MoL Pharmacol. 32, 22-30 (1988). 
39.	  Goldstein, L., and Dewitt, H. Trimethylamine oxidase of nurse shark liver and 
its relation to mammalian mixed-function amine oxidase. Comp. Biochem. 
Physiol. 45B, 895-903 (1973). 
40.	  Guengerich, F. P. Cytochrome P-450 enzymes and drug metabolism. Prog. 
Drug Metab. 10, 12-54 (1987). 
41.	  Guengerich, F. P. Analysis and characterization of enzymes. In Principles 
and Methods of Toxicology, (A. W. Hayes, ed.) pp. 777-814. Raven Press, 
New York, NY (1989). 121 
42. Guo, W.-X., and Ziegler, D. M. Estimation of flavin-containing monooxygenase 
activities in crude tissue preparations by thiourea-dependent oxidation of 
thiocholine. Anal. Biochem. 193, 143-148 (1991). 
43. Guo, W.-X. A., Poulsen, L. L., and Ziegler, D. M. Use of thiocarbamides as 
selective substrate probes for isoforms of flavin-containing monooxygenases. 
Biochem. Pharmacol. 44, 2029-2037 (1992). 
44.	  Hakkola, J., Pasanen, M., Pelkonen, 0., Hukkanen, J., Evisalmi, S., Anttila, S., 
Rane, A., Mantyla, M., Purkunen, R., Saarikoski, S., Tooming, M., and 
Hannu, R. Expression of CYP1B1 in human adult and fetal tissues and 
differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in 
human placenta and cultured cells. Carcinogenesis, 18, 391-397 (1997). 
45. Han, X., and Liehr, J. G. DNA single strand breaks in kidneys of Syrian 
hamsters treated with steroidal estrogens: hormone-induced free radical 
damage preceding malignancy. Carcinogenesis 15, 997-1000 (1992). 
46.	  Hines, R. N., Cashman, J. R., Philpot, R. M., Williams, D. E., and Ziegler, D. M. 
The mammalian flavin-containing monooxygenases: molecular characteriza-
tion and regulation of expression. Toxicol. Appl. Pharmacol. 125, 1-6 (1994). 
47. Hodgson, E., and Levi, P. E. The role of flavin-containing monooxygenase in 
the metabolism and mode of action of agricultural chemicals. Xenobiotica 
22, 1175-1183 (1992). 
48. Horseman, N. D., and Yu-Lee, L.-Y. Transcriptional regulation by the helix 
bundle peptide hormones: growth hormone, prolactin, and hematopoietic 
cytokines. Endocrinol. Rev. 15, 627-649 (1994). 
50. Humbert, J. R., Hammond, K. B., Hathaway, W. E., Marcoux, J. G., and O'Brien, 
D. Trimethylaminuria - the fish odor syndrome. Lancet 1, 770-771 (1970). 
51.	  Jellinck, P. H., Forkert, P. Gek., Riddick, D. S., Okey, A. B., Michnovicz, J. J., 
and Bradlow, H. L. Ah receptor binding properties of indole carbinol and 
induction of hepatic estradiol hydroxylation. Biochem. Pharmacol. 45, 
1129-1136 (1993). 
52.	  Jellinck, P. H., Makin, H. L. J., Sepkovic, D. W., and Bradlow, H.. L. The 
influence of indole carbinols and growth hormone on the metabolism of 
4-androstenedione by rat liver microsomes. J. Steroid Biochem. Mol. 
Biol. 46, 791-798 (1993). 122 
53.	  Kaderlik, R. F., Weser, E., and Ziegler, D. M. Selective loss of liver flavin-
containing monooxygenase in rats on chemically defined diets. Prog.  
Pharmacol. Clinic. Pharmacol. 3, 95-103 (1991).  
54. Kim, D. J., Lee, K. K., Han, B. S., Ahn, B., Bae, J. H., and Jong, J. J. Biphasic 
modifying effect of indole-3-carbinol on diethylnitrosamine-induced pre-
neoplastic glutathione-S-transferase placental form-positive liver cell foci 
in Sprague-Dawley rats. Jpn. J. Cancer Res. 85, 578-583 (1994). 
55. Kim, D. J., Han, B. S., Alm, B., Hasegawa, R., Shirai, T., Ito, H., and Tsuda, 
H. Enhancement by indole-3-carbinol of liver and thyroid gland neoplastic 
development in a rat medium-term, multiorgan carcinogenesis model. 
Carcinogenesis 18, 377-381 (1997). 
56. Kociba, R. J., Keyes, D. G., Beyer, J. E., Carreon, R. M., Wade, C. E., Dittenber, 
D. A., Kalnins, R. P., Frauson, L. E., Park, C. N., Barnard, S. D., Hummel, R. 
A., and Humiston, C. G. Results of a two year chronic toxicity and oncogenicity 
study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol. Appl. Pharmacol. 
46, 279-303 (1978). 
57. Kojima, T., Tanaka, T., and Mori, H. Chemoprevention of spontaneous endo-
metrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer 
Res. 54, 1446-1449 (1994). 
58.	  Kotas, R. V., and Avery, M. E. Accelerated appearance of pulmonary surfactant 
in the fetal rabbit. J. Appl. Physiol. 30, 358-361 (1971) 
59.	  Kreiter, P. A., Ziegler, D. M., Hill, K. E. and Burk, R. P. Increased biliary 
GSSG effux from rat livers perfused with thiocarbamide substrates for the 
flavin-containing monooxygenases. Mol. Pharmacol. 26, 122-127 (1984). 
60.	  Kress, S., and Greenlee, W. F. Cell-specific regulation of human CYP1A1 and 
CYP1B1 genes. Cancer Res. 57, 1264-1269 (1997). 
61. Krueger, S. K., and Williams, D. E. Quantitation of digoxigenin-labeled DNA 
hybridized to DNA and RNA slot blots. Anal. Biochem. 229, 162-169 (1995). 
62.	  Kurelee, B. Exclusive activation of aromatic amines in the marine mussel by 
FAD-containing monooxygenase Mytilus edulis. Biochem. Biophys. Res. 
Commun. 127, 773-778 (1985). 
63.	  Lane, D. J., Pace, B., Olsen, G. J., Stahl, D. A., Sogin, M. L. and Pace, N. R. 
Rapid determination of 16S ribosomal RNA sequences of phylogenetic 
analyses. Proc. Natl. Acad. Sci. U.S.A. 82, 6955-6959 (1985). 123 
64. Lawton, M. P., Gasser, R., Tynes, R. E., Hodgson, E., and Philpot, R. M. The 
flavin-containing monooxygenase enzymes expressed in rabbit liver and lung 
are products of related but distinctly different genes. J. Biol. Chem. 265, 
5855-5861 (1990). 
65. Lawton, M. P., Cashman, J. R., Cresteil, T., Dolphin, C. T., Elfarra, A. A., Hines, 
R. N., Hodgson, E., Kimura, T., Ozols, J., Phillips, I. R., Philpot, R. M., 
Poulsen, L. L., Rettie, A. E., Shephard, E. A., Williams, D. E. and Ziegler, 
D. M. A nomenclature for the mammalian flavin-containing monooxygenase 
gene family based on amino acid sequence identities. Arch. Biochem. 
Biophys. 308, 254-257 (1994). 
66. Laemmli, U. K. Cleavage of structural proteins during the assembly of the 
head of bacteriophase T4. Nature 227, 680-685 (1970). 
67.	  Larsen-Su, S., and Williams, D. E. Dietary indole-3-carbinol inhibits FMO 
activity and the expression of flavin-containing monooxygenase form 1 in 
rat and intestine. Drug. Metab. Dispos. 24, 927-931 (1996). 
68.	  Lee, M.-Y., Clark, J. E. and Williams, D. E. Induction of flavin-containing 
monooxygenase (FMO B) in rabbit lung and kidney by sex steroids and 
glucocorticoids. Arch. Biochem. Biophys. 302, 332-336 (1993). 
69.	  Lee, M.-Y., Smiley, S., Kadkhodayan, S., Hines, R. N., and Williams, D. E. 
Developmental regulation of flavin-containing monooxygenase (FMO) 
isoforms 1 and 2 in pregnant rabbit. Chem.-Biol. Interact. 96, 75-85 
(1995). 
70.	  Liehr, J. G., and Roy, D. Free radical generation by redox cycling of estrogens. 
Free Rad. Biol. Med. 8, 415-423 (1990). 
71.	  Liener, J. E. Toxic constituents of plant foodstuff., 2" edition. Academic 
Press, Inc., New York. pp. 502 (1980). 
72.	  Liu, H., Wormke, M., Safe, S., and Bjeldanes, L. F. Indolo(3,2-b)carbazole: 
a dietary-derived factor that exhibits both antiestrogenic and estrogenic 
activity. J. Natl. Cancer Inst. 86, 1758-1765 (1994). 
73.	  Lomri, N., Gu, Q., and Cashman, J. R. Molecular cloning of the flavin-containing 
monooxygenase (form II) cDNA from adult human liver. Proc. Natl. Acad. 
Sci. U.S.A. 89, 1685-1689 (1992). 
74. Loub, W. D., Wattenberg, W., and David, D. W. Aryl hydrocarbon hydroxylase 
induction in rat tissues by naturally occurring indoles of curciferous plants. 
J. Natl. Cancer Inst. 54, 985-988 (1975). 124 
75. Lovenberg, W. Psycho- and vasoactive compounds in food substances. J. Agri. 
Food Chem. 22, 23-26 (1974). 
76. Lowry, 0. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein 
measurement with Folin phenol reagent. J. Biol. Chem. 193, 265-275 
(1951). 
77.	  Lucier, G. W., Tritscher, A., Goldsworthy, T., Foley, J., Clark, G., Goldstein, J., 
and Maronpot, R. Ovarian hormones enhance 2,3,7,8-tetrachlorodibenzo-p-
dioxin-mediated increases in cell proliferation and preneoplastic foci in a 
two-stage model for rat hepatocarcinogenesis. Cancer Res. 51, 1391-1397 
(1991). 
78. Mani, C., and Kupfer, D. Cytochrome P-450-mediated activation and 
irreversible binding of the antiestrogen tamoxifen in proteins in rat and 
human liver: possible involvements of flavin-containing monooxygenases 
in tamoxifen activation. Cancer Res. 51, 6052-6058 (1991). 
79. McDannell, R., McLean, A. E. M., Hanley, A. B., Heaney, R. K., and Fenwick, 
G. R. Chemical and biological peroperties of indole glucosinolates (gluco-
brassicins). Fd. Chem. Toxicol. 26, 59-70 (1988). 
80.	  Miller, A. E., Bischoff, J. J., and Pae, K. Chemistry of aminoiminomethane-
sulfinic and sulfonic acids related to the toxicity of thioureas. Chem. Res. 
Toxicol. 1, 169-174 (1988). 
81.	  Miller, J. A. and Surh, Y.-J. Sulfonation in chemical carcinogenesis. In 
Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity. 
(F. C. Kauffinan, ed.) Springer-Verlag, Berlin. pp. 429-457 (1994). 
82. Miranda, C. L., Chung, W., Reed, R. E., Zhao, X., Henderson, M. C., Wang, 
J.-L., Williams, D. E., and Buhler, D. R. Flavin-containing monooxygenase: 
a major detoxifying enzyme for the pyrrolizidine alkaloid senecionine in 
guinea pig tissues. Biochem. Biophys. Res. Commun. 178, 546-552 
1991. 
83.  Mitchell, S. C. The fish-odor syndrome. Persp. Biol. Med. 39, 514-526 (1996). 
84.	  Nagata, T., Williams, D. E., and Ziegler, D. M. Substrate specificities of 
rabbit lung and porcine liver flavin-containing monooxygenases: differ-
ences due to substrate specificity. Chem. Res. Toxicol. 3, 372-376 (1990). 125 
85. Newfield, L. A., Goldsmith, A., Brad low, H. L., and Auborn, K. Estrogen 
metabolism and human papilloma virus-induced tumors of the larynx: 
chemoprophylaxis with indole-3-carbinol. Anticancer Res. 13, 337-342 
(1993). 
86.	  Nikbakht, K. N., Lawton, M. P., and Philpot, R. M. Guinea-pig or rabbit lung 
flavin-containing monooxygenases with distinct mobilities in SDS-PAGE 
are allelic variants that differ at only 2 positions. Pharmacogenetics 2, 
207-216 (1992). 
87. Nixon, J. E., Hendricks, Pawlowski, N. E., Pereira, C., Sinnhuber, R. 0., and 
Bailey, G. S. Inhibition of aflatoxin B1 carcinogenesis in rainbow trout by 
flavone and indole compounds. Carcinogenesis 5, 615-619 (1984). 
88. Ohmiya, Y., and Mehendale, H. M. Metabolism of chlorpromazine by pulmon-
ary microsomal enzymes in the rat and rabbit. Biochem. Pharmacol. 31, 
157-162 (1982). 
89. Ohmiya, Y., and Mehendale, H. M. N-oxidation of N,N-dimethylaniline 
in the rabbit and rat lung. Biochem. Pharmacol. 32, 1281-1285 (1983). 
90. Ohmiya, Y., and Mehendale, H. M. Effect of mercury on accumulation and 
metabolism of chlorpromazine and imipramine in rat lungs. Drug Metab. 
Dispos. 12, 376-378 (1984). 
91.	  Okey, A. B. Enzyme induction in the cytochrome P-450 system. Pharmac. 
Therap. 45, 241-298 (1990). 
92.	  Park, S. B., Jacob, P., III, Benowitz, N. L., and Cashman, J. R. Stereoselective 
metabolism of (S)-(-)-nicotine in humans: formation of trans- (S) -( -)-
nicotine N-1'-oxide. Chem. Res. Toxicol. 6, 880-888 (1993). 
93. Pence, B. C., Buddingh, F., and Yang, S. P. Multiple dietary factors in the 
enhancement of dimethylhydrazine carcinogenesis: main effect of indole-
3-carbinol. J. Natl. Cancer Inst. 77, 269-276 (1986). 
94.	  Poulsen, L. L. and Ziegler, D. M. Microsomal mixed function oxidase-dependent 
renaturation of reduced ribonuclease. Arch. Biochem. Biophys. 183, 563-570 
(1977). 
95.	  Poulsen, L. L., and Ziegler, D. M. The liver microsomal FAD-containing 
monooxygenase. Spectral characterization and kinetic studies. J. Biol. Chem. 
254, 6449-6455 (1979). 126 
96.	  Poulsen, L. L., and Ziegler, D. M. Multisubstrate flavin-containing mono-
oxygenase: application of mechanism to specificity. Chem.-Biol. Interact. 
96, 57-73 (1995). 
97. Prough, R. A., Freeman, P. C., and Hines, R. N. The oxidation of hydrazine 
derivatives catalyzed by the purified microsomal FAD-containing mono-
oxygenase. J. Biol. Chem. 256, 4178-4184 (1981). 
98.	  Rettie, A. E., Bogucki, B. D., Lim, I, and Meier, G. P. Stereoselective sulfoxi-
dation of a series of alkyl-p-tolylsulfides by microsomal and purified flavin-
containing monooxygenases. MoL Pharmacol. 37, 643-651 (1990). 
99. Reyes, H., Reisz-Porszasz, S., and Hankinson, 0. Identification of the Ah 
receptor nuclear translocation protein (Arnt) as a component of the DNA 
binding form of the Ah receptor. Science 256, 1193-1195 (1992). 
100. Sadeque, J., Thummel, K. E., and Rettie, A. E. Purification of macaque liver 
flavin-containing monooxygenase: a form of the enzyme related immuno-
logically to an isozyme expressed selectively in adult human liver. Biochim. 
Biophys. Acta. 1162, 127-134 (1993). 
101. Salbe, A. D., and Bjeldanes, L. F. Dietary influences on rat hepatic and 
intestinal DT-diaphorase activity. Fd. Chem. Toxicol. 24, 851-856 (1986). 
102. Savas, U., Bhattacharyya, K. K., Christou, M., Alexander, D. L., and Jefcoate, 
C. R. Mouse cytochrome P-450EF, representative of a new 1B subfamily 
of cytochrome P-450s. Cloning, sequence determination, and sequence 
expression. J. Biol. Chem. 269, 14905-14911 (1994). 
103. Shehin-Johnson, S. E., Williams, D. E. Larsen-Su, S., Stresser, D. M. and Hines, 
R. N. Tissue-specific expression of flavin-containing monooxygenase (FMO) 
forms 1 and 2 in the rabbit. J. Pharmacol. Exptl. Therap. 272, 1293-1299 
(1995). 
104. Shehin-Johnson, S. E., Palmer, K. C., and Hines, R. N. Identification of tissue-
specific DNAse I hypersensitive sites on the rabbit flavin-containing mono-
oxygenase for 2 gene. Drug Metab. Dispos. 24, 891-898 (1996). 
105. Shepherd, E. A., Dolphin, C. T., Fox, M. F., Povey, S., Smith, R., and Phillips, 
I. R. Localization of genes encoding three distinct flavin-containing mono-
oxygenases to human chromosome lq. Genomics 16, 85-89 (1993). 
106. Shertzer, H. G., Berger, M. L., and Tabor, M. W. Intervention in free radical 
mediated hepatotoxicity and lipid peroxidation by indole-3-carbinol. 
Biochem. Pharmacol. 37, 333-338 (1988). 127 
107. Shertzer, H. G., and Sinsbury, M. Intrinsic acute toxicity and hepatic enzyme 
inducing properties of the chemoprotectants indole-3-carbinol and 5,10-di-
hydroindeno141,2-b]indole in mice. Fd. Chem. Toxicol. 29, 237-242 
(1991). 
108. Schlenk, D., and Buhler, D. R. Xenobiotic transformation in the Pacific oyster 
(Crassostrea gigas). Comp. Biochem. Physiol. 94, 469-475 (1989). 
109. Schlenk, D., and Buhler, D. R. Flavin-containing monooxygenase activity in the 
gumboot chiton Cryptochiton stelleri. Mar. Biol. 104, 47-50 (1990). 
110. Schlenk, D., and Buhler, D. R. Flavin-containing monooxygenase activity in 
liver microsomes from the rainbow trout (Oncorhynchus mykiss). Aquat. 
Toxicol. 20, 13-23 (1991). 
111. Sparnius, V. L., Venegas, P. L., and Wattenberg, L. W. Glutathione S-transferase 
activity: enhancement by compounds inhibiting chemical carcinogenesis and 
and by dietary constituents. J. Natl. Cancer Inst. 68, 493-493 (1982). 
112. Stresser, D. M., Bailey, G. S., and Williams, D. E. Indole-3-carbinol and 
p-naphthoflavone induction of aflatoxin B1 metabolism and cytochromes 
P-450 associated with bioactivation and detoxication of aflatoxin B1 in 
the rat. Drug Metab. Dispos. 22, 383-391 (1994). 
113. Stresser, D. M., Bjeldanes, L. F., Bailey, G. S., and Williams, D. E. The anti-
carcinogen 3,3'-diindolylmethane is an inhibitor of cytochrome P-450. 
.1 Biochem. Toxicol. 10, 191-201 (1995). 
114. Stresser, D. M., Williams, D. E., Griffin, D. A., and Bailey, G. S. Mechanisms 
of tumor modulation by indole-3-carbinol. Disposition and excretion in male 
Fischer 344 rats. Drug Metab. Dispos. 23, 965-974 (1995). 
115. Takahashi, N., Dashwood, R. H., Bjeldanes, L. F.., Bailey, G. S., and Williams, 
D. E. Regulation of hepatic cytochrome P4501A by indole-3-carbinol: 
transient induction with continuous feeding in rainbow trout. Fd. Chem. 
Toxicol. 33, 111-120 (1995). 
116. Towbin, H., Staehelin, T., and Gordon, J. Electrophoretic transfer of proteins 
from polyacrylamide gels to nitrocellulose sheets: procedure and some 
applications. Proc. Natl. Acad. Sci. U.S.A.. 76, 4350-4354 (1979). 128 
117. Tynes, R. E., Sabourin, P. J., and Hodgson, E. Identification of distinct hepatic 
and pulmonary forms of microsomal flavin-containing monooxygenase in 
the mouse and rabbit. Biochem. Biophys. Res. Commun. 126, 1069-1075 
(1985). 
118. Walker, N. J., Gastel, J. A., Costa, L. T., Clark, G. C., Lucier, G. W., and Sutter, 
T. R. Rat CYP1B1: an adrenal cytochrome P450 that exhibits sex-dependent 
expression in livers and kidneys of TCDD-treated animals. Carcinogenesis 
16, 1319-1327 (1995). 
119. Wattenberg, L. W., and Loub, W. D. Inhibition of polycyclic aromatic hydro-
carbon-induced neoplasia by naturally occurring indoles. Cancer Res. 38, 
1410-1413 (1978). 
120. Williams, D. E., Ziegler, D. M., Nordin, D. J., Hale, S. E., and Masters, B. S. S. 
Rabbit lung flavin-containing monoxygenase is immunochemically and 
catalytically distinct from the liver enzyme. Biochem. Biophys. Res. 
Commun. 125, 116-122 (1984). 
121.	  Williams, D. E., Hale, S. E., Muerhoff, A. S., and Masters, B. S. S. Rabbit 
lung flavin-containing monooxygenase: purification, characterization and 
induction during pregnancy. Mol. Pharmacol. 28, 381-390 (1985). 
122. Williams, D. E., Reed, R. L., Kedzierski, B., Ziegler, D. M., and Buhler, D. R. 
The role of flavin-containing monooxygenases in the N-oxidation of the 
pyrrolizidine alkaloid senecionine. Drug Metab. Dispos. 17, 380-386 (1989). 
123. Williams, D. E. Factors regulating the activity of the rabbit lung flavin-
containing monooxygenase. In N-Oxidation of Drugs: Biochemistry, 
Pharmacology and Toxicology, (P. Hlavica and L. A. Damani, eds.), 
Chapman and Hall, New York, NY, pp. 91-105 (1991). 
124. Wortelboer, H. M., van der Linden, E. C. M., deKruif, C. A., Noordhoek, J., 
Blaauboer, B. J., van Bladeren, P. J., and Falke, H. E. Effects of indole-3-
carbinol on biotransformation enzymes in the rat: in vivo changes in liver 
and small intestinal mucosa in comparison with primary hepatocyte cultures. 
Fd. Chem. Toxicol. 30, 589-599 (1992). 
125. Wyatt, M. K., Philpot, R. M., Carver, G., Lawton, M. P., and Nikbakht, K. N. 
Structural characteristics of flavin-containing monooxygenase genes one 
and two (FMO1 and FMO2). Drug Metab. Dispos. 24, 1320-1327 (1996). 129 
126. Yueh, M.-F., Krueger, S. K., and Williams, D. E. Pulmonary flavin-containing  
monooxygenase (FMO) in rhesus macaque: expression of FMO2 protein,  
mRNA and analysis of the cDNA. Biochim. Biophys. Acta. 1350, 267-
271 (1997).  
127. Zarrow, M. X., Farocq, A., Denenberg, V. H., Swain, P. B., and Ross, R. 
Maternal behavior in the rabbit: endocrine control of maternal nest 
building.  J. Repro. Fert. 6, 375-383 (1963). 
128. Ziegler, D. M., and Petit, F. H. Formation of an intermediate N-oxide in the 
oxidative demethylation of N,N-dimethylaniline catalyzed by liver micro-
somes. Biochem. Biophys. Res. Commun. 15, 188-193 (1964). 
129. Ziegler, D. M., Poulsen, L. L. and McGee, E. M. Interaction of primary amines 
with a mixed-function amine oxidase isolated from pig liver microsomes. 
Xenobiotica 1, 523-531 (1971). 
130. Ziegler, D. M., and Mitchell, C. H. Microsomal oxidase IV: Properties of a 
mixed-function amine oxidase isolated from pig liver microsomes. Arch. 
Biochem. Biophys. 150, 116-125 (1972). 
131. Ziegler, D. M. and Poulsen, L. L. Hepatic microsomal mixed function amine 
oxidase. In Methods in Enzymology (S. Fleischer and L. Packer, eds.) 
Academic Press, New York, NY, Vol. 52, Part C, pp. 142-151 (1978). 
132. Ziegler, D. M. Microsomal flavin-containing monooxygenase: oxygenation of 
nucleophilic nitrogen and sulfur compounds. In Enzymatic Basis of Detoxi-
cation (W. B. Jakoby, ed.) Academic Press, New York, NY, Vol. 1, pp. 201-
277 (1980). 
133. Ziegler, D. M. Metabolic oxygenation of organic nitrogen and sulfur compounds. 
In Drug Metabolism and Drug Toxicity, (J. R. Mitchell and M. G. Horning, 
eds.) Raven Press, New York, pp. 1-31 (1984). 
134. Ziegler, D. M. Rose of reversible oxidation-reduction of enzyme thiol-disulfides 
in metabolic regulation. Annu. Rev. Biochem. 54, 305-329 (1985). 
135. Ziegler, D. M., Ansher, S. L., Nagata, T., Kadlubar, F. F., and Jakoby, W. B. 
N-methylation: potential mechanism for metabolic activation of carcinogenic 
primary arylamines. Proc. Natl. Acad. Sci. U.S.A. 85, 2514-2517 (1988). 
136. Ziegler, D. M. Flavin-containing monooxygenases: catalytic mechanism and 
substrate specificities. In Drug Metabolism Review (F. J. DiCarlo, ed.) 
Marcel Dekker, Inc., New York, pp. 1-32 (1988). 130 
137. Ziegler, D. M. Bioactivation of xenobiotics by flavin-containing monooxygenase. 
Biological reactive intermediates IV, (C. Witmer, ed.) Plenum Press, New York, 
NY. pp. 41-50 (1990). 
138. Ziegler, D. M. Mechanism, multiple forms and substrate specificities of flavin-
containing monooxygenases. Human pharmacogenetics of nitrogen oxidation. 
In N-Oxidation of Drugs: Biochemistry, Pharmacology, Toxicology. (Hlavica 
and Damani, eds.) Chapman & Hall, London. pp. 59-68 (1991). 
139. Ziegler, D. M. Recent studies on the structure and function of multisubstrate 
flavin-containing monooxygenases. Ann. Rev. Pharmacol. Toxicol. 33, 
179-199 (1993). 